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that can be made in a very narrow field.”
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ABSTRACT
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the 
extracellular aggregation of the amyloid-β (Aβ; amyloid) peptide and the intra-
neuronal accumulation of the protein tau. Independently, and in concert, these 
protein opathies lead to the loss of synapses and neurons (neurodegeneration). These 
processes can be measured in living individuals using positron emission tomog-
raphy (PET) and cerebrospinal fluid (CSF) based measurements (biomarkers). 
Biomarkers for AD include the retention in the brain of varied PET ligands (e.g. 
[11C]PIB and [18F]flutemetamol, Aβ; [18F]THK5317, tau; and [18F]FDG, glucose 
metabolism, a proxy for synaptic integrity), as well as CSF levels of Aβ1-42, and 
tau phosphorylated at threonine 181 (p-tau181p), and total-tau (t-tau), reflecting Aβ, 
the formation tau tangle pathology, and axonal damage, respectively. The aim of 
this thesis, which comprises five studies, was to obtain new insight into how these 
biomarkers interrelate in AD, and to examine their potential utility from a clinical 
standpoint. In study I, agreement between dichotomised (i.e. normal/abnormal) 
[11C]PIB PET and CSF Aβ1-42 in AD and related disorders was found to persist 
after controlling for potential methodological confounds tied to CSF, suggesting 
biological underpinnings to biomarker mismatches. Concordance, however, was 
substantially improved across patient groups when using Aβ1-42 in ratio with Aβ1-40. In 
study II, the impact of amyloid imaging with [18F]flutemetamol PET was examined 
in a cohort of diagnostically unclear patients, drawn from a tertiary memory clinic. 
[18F]Flutemetamol investigations resulted in substantial changes to pre-amyloid 
PET diagnoses and an incease in the use of cholinesterase inhibitors, with the 
greatest impact seen among patients with a pre-[18F]flutemetamol diagnosis of 
MCI. In study III, the relationship between [18F]THK5317 tau PET and CSF tau, 
including measures derived from assays capturing novel fragments, was shown to 
vary by isocortical hypometabolism, suggesting that the relationship between tau 
biomarkers may vary by disease stage. Novel CSF markers better tracked longi-
tudinal PET, as compared to p-tau181p and t-tau, and improved concordance with 
[18F]THK5317. Moreover, comparison of cross-sectional and rate of change  findings 
suggest a temporal delay between tau pathology and synaptic impairment. In  studies 
IV and V, perfusion information derived from [18F]THK5317 tau PET scans was 
shown to strongly correlate with [18F]FDG PET metabolic imaging; though our 
cross-sectional data support the use of perfusion parameters as a substitute for 
[18F]FDG, longitudinal findings suggest that the coupling between perfusion and 
metabolism may vary as a function of disease stage, warranting further studies.
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11 INTRODUCTION
1.1 FROM NORMAL AGEING TO DEMENTIA
1.1.1 Cognitive changes in ageing
Cognition refers to the mental functions involved in thinking, attention, understand-
ing, learning, remembering, problem solving, and decision making.1 Cognitive 
ageing can be defined as a process of change in cognitive functioning that occurs 
as people get older; this process, however, though gradual and ongoing, is highly 
variable, both across and within individuals, as well as cognitive domains.2 Studies 
attempting to elucidate the mechanisms underlying this phenomenon suggest that 
it relates to changes in synaptic structure and function, as opposed to neuronal loss.2 
Though cognitive ageing is not a disease per se, distinguishing it from the initial 
phase of a neurodegenerative disease can prove challenging.
1.1.2 Dementia and the changing demography of ageing
Dementia can be described as the acquired loss of cognitive functioning, sufficient 
to interfere with independence in everyday activities.3 Worldwide, an estimated 
47 million people currently live with dementia, with this figure projected to reach 
82 million by 2030.4 With increasing age as the greatest risk factor for dementia, a 
driving factor behind these rising prevalence figures is increased longevity, a factor 
that has produced a demographic shift resulting in a rapid growth in the number 
of elderly individuals.5 Indeed, census bureau projections indicate that there will 
be more than 2.1 billion people over age 65 by the year 2050.6 Given the immense 
social and economic costs tied to the treatment of dementia, and the fact that age 
is its strongest risk factor, the World Health Organization has recently advocated 
that dementia be considered as a global public health priority7,8 
1.1.2.1. Dementia disorders
The term dementia does not refer to a single disease but rather to a variety of 
clinico-pathological entities, exhibiting both distinct and overlapping character-
istics. Alzheimer’s disease (AD) is the leading cause of dementia, accounting for 
between 50 and 70 percent of all cases using current clinical criteria.5 Other causes 
of dementia include cerebrovascular disease, frontotemporal lobar degenera-
tion, and Lewy body pathology. Autopsy verified studies suggest that most cases 
of dementia are due to multiple brain pathologies, including α-synuclein and 
hyperphosphorylated transactive response DNA-binding protein 43 (TDP-43),9 
with AD and a vascular component the most frequent combination; importantly, 
mixed pathologies show increased prevalence with advancing age.10 Finally, addi-
tional diseases have been linked to dementia, including traumatic brain injury,11 
Parkinson’s disease (PD),12 Creutzfeldt–Jakob disease,13 and Down’s syndrome,14 
as well as reversible conditions such as normal pressure hydrocephalus, encephalitis, 
and depression15 (Figure 1).  
21.1.3 Subjective cognitive decline
Subjective cognitive decline (SCD), or self-perceived impairment in cognitive func-
tion in the absence of objective impairment, has gained growing attention from the 
scientific community. Though investigators have struggled to achieve a common 
definition and standardised assessment approach16,17 since its initial description,18 the 
presence of SCD has been shown to be associated with the emergence of objective 
cognitive impairment and with progression to mild cognitive impairment (MCI 
and even dementia.19 Moreover, in comparison to those without SCD, individuals 
with SCD more often show AD-like biological marker (biomarker) findings (here 
defined as an objective measure of brain pathology including the accumulation 
of amyloid-β (Aβ; amyloid) and tau,20-22 as well as neurodegenerative (decreased 
glucose metabolism and greater atrophy in AD signature regions)23-25 and functional 
(disrupted default mode network connectivity) changes.26,27 Research criteria for 
SCD have been put forth28,29 along with the proposal that SCD may represent late-
stage preclinical AD (a protracted period during which AD pathology accumulates 
in the brain in the absence of symptoms; subtle cognitive decline, i.e. from personal 
baseline, however, has also been reported as a feature). 41, 534
MCI
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Figure 1. Waffle plot showing the distribution of diagnostic categories among patients 
seen due to cognitive complaints at the Clinic for Cognitive Disorders, Theme Aging, 
Karolinska University Hospital, Stockholm, Sweden (n=580, data from 2017). Each 
square represents one percent: MCI, mild cognitive impairment (37%); AD, Alzheimer’s 
disease (22%); SCD, subjective cognitive decline (24%), VaD, vascular dementia (4%), 
FTLD, frontotemporal lobar degeneration (3%); Mixed, mixed dementia (4%); DLB 
& NOS, dementia with Lewy bodies and dementia not otherwise specified (3%); RCD, 
reversible cognitive disorder due to other medical condition (3%).
31.1.4 Mild cognitive impairment
The concept of MCI was introduced to describe a state of cognitive impairment 
intermediate between those due to normal ageing and dementia due to AD.30-32 This 
diagnosis applies to individuals exhibiting objective cognitive impairment, beyond 
that expected given their age and education, yet of insufficient severity to meet 
criteria for dementia. Patients with MCI represent a heterogeneous group, with 
underlying causes ranging from functional disturbances (e.g. depression, drugs 
and alcohol) to pathological entities (e.g. AD, vascular disease). When patients 
with MCI are followed over time, some progress to AD or other forms of demen-
tia (approximately 15% per year), while others remain stable or even recover, 
reverting to a cognitively unimpaired state.33,34 Though originally defined as an 
amnestic syndrome, advances in research on MCI have made apparent the exist-
ence of nonamnestic subtypes, as well as the designation of single or multi-domain 
impairment.35-37 In light of some of the disadvantages of the concept of MCI,38,39 
the term prodromal AD was introduced in an effort to capture those MCI patients 
with AD as the underlying pathology, incorporating a specific type of memory 
loss (impaired free recall that does not normalise with cueing)40 and supportive 
biomarker evidence.41-43 In practice, however, the designation of prodromal AD is 
often applied in the absence of this specific amnestic profile (i.e. in cases of MCI 
who show amyloid positivity). Similar to this term is that of MCI due to AD;44 
here, cognitive impairment is not restricted to memory, with the likelihood (high, 
intermediate, or unlikely) that the syndrome of MCI is due to AD established on 
the basis of biomarker information.  
1.2 ALZHEIMER’S DISEASE
The first set of diagnostic criteria for the clinical diagnosis of AD were put forth 
in 1984 by a working group established by the National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA).45 According to these criteria, AD could 
be diagnosed in the presence of a progressive dementia syndrome with an amnestic 
component, not better accounted for by other neurologic, psychiatric, or systemic 
disorders; the designation of probable or possible, was also included, depending on 
the presence of other diseases and typicality of the clinical presentation and course. 
Importantly, these criteria rested on the notion that a close, one-to-one correspond-
ence existed between clinical symptoms and the underlying AD pathology; as such, 
those meeting the criteria were assumed to have fully developed pathology, with 
no recognition of the concept of cognitive impairment in the absence of dementia 
(i.e. MCI).46 Further, an only very minor role was ascribed to the use of biological 
parameters, with these used mainly to exclude other potential causes of dementia. 
41.2.1 Neuropathology
AD pathology can broadly be divided into positive lesions due to accumulation 
(amyloid and hyperphosphorylated tau), negative lesions due to tissue loss (reflecting 
neurodegenerative changes, including synaptic and neuronal depletion) and reactive 
processes (neuroinflammation, involving microglial activation and astrocytosis)47 
(Figure 2).
Figure 2. Overview of plaque and tangle pathology in Alzheimer’s disease. Following its 
cleavage from the amyloid precursor protein (APP; step 1), amyloid‑β (Aβ) is released 
into the extracellular space in the form of diffusible oligomers (Aβo). These can be taken 
up through APOE related mechanisms or cleared via astrocytes (low-density lipoprotein 
receptor‑related protein 1 (LRP1; step 2). Aggregation of Aβo into fibrillary constructs 
can also occur in the intercellular space; these, in turn, can amass into plaques (step 3). 
These can be cleared via macrophages and microglia (endocytic or phagocytic degra-
dation) or by endoproteases from astrocytes (e.g. neprolysin (NEP), insulin-degrading 
enzyme (IDE), and matrix metalloproteinase (MMP); step 4). Certain oligomers, how-
ever, may prove resistant to clearance and exert synaptotoxic effects (step 5) and induce 
the aggregation of pathological forms of tau. Tau pathology occurs intracellularly, with 
tau damage mediated by neurofibrillary tangles (step 6). Fibrillary tau species can be 
secreted by affected neurons and subsequently taken up by healthy ones (step 7). Adapted 
with permission from Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, 
Cummings JL. Alzheimer’s disease. Nat Rev Dis Primers. 2015;1: 15056. Copyright 
Macmillan Publishers Ltd: Nature, 2015. 
51.2.1.1 Amyloid‑β
Though debate surrounds the events critical to the triggering of Aβ pathology,48 
possible explanations include age-related disruption of proteostatic mechanisms49,50 
and impaired clearance.51,52 Aβ peptides are known to exhibit a propensity to 
intrinsic self-assembly, producing a range of aggregates referred to as oligomers, 
protofibrils, or mature amyloid fibrils (Figure 3) on the basis of their appearance 
by electron microscopy.53,54 After following a maturation process marked by an 
increase in the concentration of soluble Aβ, post-translational modifications 
occur,55,56 resulting in the accumulation of parenchymal aggregates, primarily in 
the form diffuse or focal deposits, as well as the deposition of Aβ in the walls of 
arteries and capillaries (cerebral amyloid angiopathy; CAA).57
Figure 3. The 3D structure of an Aβ1-42 fibril, obtained using hydrogen-bonding con-
straints from quenched hydrogen/deuterium-exchange nuclear magnetic resonance. Its 
structure consists of two in‑register intermolecular stacked parallel β‑sheets that extend 
along the fibril axis.  Individual molecules are coloured (e.g. end monomer in cyan). Arrows 
indicate the β‑strands, spline curves though Cα atom coordinates of the matching  residues, 
the irregular secondary structure. Also shown are the side chain bonds that comprise the 
core of the protofilament. Dotted lines indicate the intermolecular salt bridge between 
residues D23 and K28, with the two salt bridges made up by the central Aβ molecule 
emphasised by rectangles. Adapted with permission from Lührs T, Ritter C, Adrian M, 
et al. 3D structure of Alzheimer’s amyloid-beta (1-42) fibrils. Proc Natl Acad Sci U S A. 
2005;102(48):17342-17347. Copyright National Academy of Sciences, 2005.
6Diffuse deposits are convoluted in their contour and exhibit poor immunoreactivity, 
likely due their having a low content of Aβ peptide. Though they may be crossed by 
degenerating neurites in advanced AD, this feature is typically absent.58 Aβ deposits 
are invariably diffuse in certain brain regions, including in the presubiculum and 
entorhinal cortex,59,60 and generally diffuse in the striatum and cerebellum.47 Focal 
deposits, by contrast, are spherical in shape, have a high content of 40 and 42 amino 
acid Aβ isoforms, and can be regrouped into at least three types: compact plaques, 
comprising a dense central core with no peripheral elements,58,61 immature plaques, 
reticular in appearance, possessing no clearly identifiable core,62 and the so-called 
classic or neuritic plaque, characterized by a dense amyloid core surrounded by a 
corona of tau positive processes.62 
The areal topography of Aβ parenchymal deposits have been shown to follow an 
ordered pattern of progression, with two neuropathology based staging schemes: 
according to that proposed by Braak (Figure 4), in which only the cerebral cortex is 
considered, amyloid deposits are first found in the basal areas of the cortex (stage A), 
followed by spreading to involve all isocortical areas, save the hippocampus and 
primary sensorimotor cortices (stage B), and, lastly, all isocortical areas, including 
those previously spared (stage C).63 According to Thal et al., amyloid deposition 
progresses through five phases. Phase 1 involves the isocortex, phase 2 the entorhinal 
cortex and hippocampus, phase 3 the striatum and diencephalon nuclei, phase 4 
certain brainstem nuclei, and, finally, the cerebellum and remaining brainstem 
nuclei in phase 5.64A specific pattern of Aβ progression has also been described 
for the medial temporal lobe.65 Though these patterns of progression are based 
on cross sectional data from different brains (thus amounting to an extrapolation 
only), recent in vivo based staging of amyloid deposition using positron emission 
tomography (PET) in a large number of individuals across the AD continuum has 
shown findings consistent with these neuropathologic staging schemes.66 
1.2.1.2 Tau pathology
The microtubule-associated protein tau (MAPT) is natively unfolded and plays a 
major role in the assembly and stability of microtubules.67 In the adult human brain, 
six isoforms of tau are produced via alternative mRNA splicing of the MAPT gene 
on chromosome 17,68-70 yielding two functionally distinct groups, possessing either 
three or four repeats of the microtubule-binding domain (3R and 4R tau, respec-
tively).71 Equally expressed in the healthy adult brain, 3R and 4R isoforms undergo 
varying degrees of hyperphosphorylation in neurodegenerative disorders in which 
the pathological accumulation of tau is seen (tauopathies); while both are equally 
involved in AD, other disorders are characterized by involvement of predominantly 
3R (e.g. Pick’s disease) or 4R (e.g. progressive supranuclear palsy; PSP) tau.71,72 
7In contrast to Aβ pathology, tau pathology accumulates intracellularly, within both 
the somatodendritic and axonal compartments of neurons.73 Following hyperphos-
phorylation, tau aggregates into β-sheet paired helical filaments (Figure 5). On 
the basis of their isoform, tau inclusions adopt differing morphologies.74,75 In AD, 
neurofibrillary tangles (NFTs) are found, composed of paired helical filaments 
(PHFs), and, to a lesser degree, straight filaments.76,77 As a result of neurofibrillary 
pathology being only partially cleared from the brain, the density of alterations has 
been shown to correlate with disease severity and cognitive impairment, allowing 
for the tracking of disease progression.47,78 
Though the mechanisms mediating tau pathology are as yet unclear – with possible 
explanations including age related deficiencies in the proteostatic network49,50 and 
faulty clearance mechanisms,51,52 as for amyloid – its deposition and spread has been 
shown to follow a characteristic topography, first described by Braak and Braak.63 
A B
Figure 4. Evolution of amyloid and tau pathology in Alzheimer’s disease Amyloid plaques 
and neurofibrillary tangles (a) spread through the brain as the disease progresses. Cortical 
amyloid deposition can be divided into three stages (b): basal neocortex (stage A), adjoin-
ing neocortical areas and the hippocampal formation (stage B), and the whole cortex 
(stage C). For tau pathology, the transentorhinal region followed by the entorhinal region 
proper are the first areas to be (stage I and II), followed by spreading to include both the 
hippocampus and the temporal proneocortex and adjoining neocortex (stage III and IV).  
Eventually, the lesions spread superolaterally, extending into primary neocortical areas 
(stage V and VI). Adapted with permission from Masters CL, Bateman R, Blennow K, 
Rowe CC, Sperling RA, Cummings JL. Alzheimer’s disease. Nat Rev Dis Primers. 2015; 
1:15056. Copyright Macmillan Publishers Ltd: Nat Rev Dis Primers, 2015. 
8According to their staging system, tau begins in trans-entorhinal and entorhinal 
regions (stages I/II), followed by limbic (stage III/IV) and neocortical involve-
ment, including primary and secondary fields (stages V/VI) (Figure 4). Convergent 
findings have also been described by Delacourte et al., save with progression 
regrouped into 10 stages.79 Similar to amyloid, however, these studies are based 
on cross sectional findings from comparatively few cases. Using tau PET, though, 
several cross-sectional in vivo studies have shown patterns of tracer uptake consist-
ent with Braak staging;80-82 exceptions have been reported, however,83 including 
longitudinal findings showing that patterns of accumulation in pathologic tau can 
differ from those expected based on the Braak model.84
1.2.1.3 Neurodegeneration
Two aspects can define synaptic pathology in AD: synaptic involvement in senile 
plaques85 and declines in the total number of synapses over time. Pre-synaptic 
markers such as synaptophysin have been shown to be decreased be decreased arly 
on in the course of AD,86 leading to synaptic loss being viewed as the best cor-
relate of cognitive decline.87,88 Further studies, however, showed that cognitive 
decline better correlated with tau pathology, relative to the drop in synaptophysin 
 immunoreactivity.89,90 Levels of synaptic proteins, including the presynaptic vesicle 
A
B
Figure 5. The 3D structure of the tau protofilament core obtained by cryo-electron  microscopy. 
(a) Sequence alignment of the four microtubule-binding repeats (R1–R4) with the observed 
eight β‑strand regions coloured from blue to red. (b) Rendered view of the secondary struc-
ture elements in three successive rungs. Adapted with permission from Fitzpatrick AWP, 
Falcon B, He S, et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. 
Nature. 2017;547(7662):185-190. Copyright Macmillan Publishers Ltd: Nature, 2017.
9protein synapto tagmin,91 the presynaptic membrane protein SNAP-25,91,92 and the 
dendritic protein neurogranin,91,93 have also been shown to be reduced in in the 
AD brain, reflecting the degeneration and loss of synapses. 
Though mixed findings have been documented with respect to the global number 
of cortical neurons affected in AD,94 severe neuronal loss has been shown in the 
entorhinal cortex95 and hippocampus (CA1 section),96 as well as in the superior 
temporal and supramarginal gyri.97 While the regional and laminar distribution of 
neuronal loss has been shown to match that of NFTs, he former has been shown 
to exceed the latter within the same region such that the contribution of neuronal 
and, presumably, synaptic loss, may exceed that of NFT count with respect to 
cognitive decline.95,98 The dissociation between neuronal death and the extent of 
NFTs suggests that at least two mechanisms may underlie neuronal loss in AD: 
one targeting tangle-bearing neurons, resulting in the appearance of extracellular 
NFTs (so-called ghost tangles), and one affecting tangle-free neurons.99
1.2.1.4 Neuroinflammation
After a series of classic studies implicating complement factors in the formation of 
Aβ plaques,100-103 numerous post-mortem biochemical, immunohistochemical, and 
molecular findings have confirmed the presence of reactive microglia and astro-
cytes in the brains of individuals with AD.104-106 While the relationship between 
neuroinflammation, Aβ, and tau pathology remains uncertain, glial activation 
has been shown to play a role in the removal of various forms of Aβ107-110 and to 
correlate with the density of neurofibrillary and Aβ deposits and clearance.111-113 
Opposing views have been voiced regarding the significance of these processes in 
AD, however, with some proposing that they are protective, others, deleterious.114,115 
Possibly, the effects of glial activation may vary by disease stage; specifically, in 
vivo studies using cerebrospinal fluid (CSF) and PET based markers of microglial 
activation (TREM2 and [11C](R)PK11195, respectively) suggest that microglial 
activation may shift from an initially protective phenotype during the presympto-
matic/MCI stages of AD, to a pro-inflammatory one during the dementia phase.116-119
1.2.1.5 Neuropathological criteria for AD
Recommendations for the neuropathological diagnosis of AD were first proposed 
in 1985, in the form of a specified age-dependent numerical cut-off for senile Aβ 
plaques.120 Additional criteria were subsequently proposed, incorporating method-
ologies for the assessment and staging of NFT pathology.121,122 The most recent 
criteria,123 proposed by the National Institute on Aging and Alzheimer’s Association 
(NIA-ΑA), incorporate staging schemes for Aβ deposits (Thal),64  tangle pathology 
(Braak),63,124 and neuritic plaque severity (Consortium to Establish a Registry for 
Alzheimer’s Disease; CERAD) (Table 1).121 
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Table 1. Neuropathologic criteria for the diagnosis of AD.
A: Aβ plaque score 
(Thal phases) †
B: NFT score 
(Braak stage) ††
C: Neuritic plaque 
score (CERAD) †††
B0 or B1  
(None or I/II)
B2  
(III/IV)
B3  
(V/VI)
A0  
(0)
Not Not Not C0  
(none)
A1  
(1/2)
Low Low Low C0 or C1  
(none to sparse)
Low Intermediate Intermediate C2 or C3  
(mod. to freq.) 
A2  
(3)
Low Intermediate Intermediate Any C
A3  
(4/5)
Low Intermediate Intermediate C0 or C1  
(none to sparse)
Low Intermediate High C2 or C3  
(mod. to freq.)
AD neuropathologic change is evaluated using an ABC score, derived from three  separate 
4-point scales: Aβ/amyloid plaques (A) using Thal phases, NFT burden (B) using Braak  staging 
and a neuritic plaque score (C) using the protocol from CERAD. Resulting ABC scores are rated 
as  “Not,” “Low,” Intermediate,” or “High” for AD neuropathologic change, with “Inter mediate” or 
“High” considered sufficient to account for dementia. CERAD, Consortium to Establish a Registry 
for Alzheimer’s disease; mod., moderate; freq., frequent.
†Aβ/amyloid plaque score should be determined according to the method of Thal: Thal DR, Rub U, 
Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the 
development of AD. Neurology. 2002;58(12):1791-1800.
†† NFT stage should be determined by the method of Braak: Braak H, Braak E. Neuropathological 
stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259; Braak H, Alafuzoff I, 
Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neuro-
fibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 
2006;112(4):389-404; 
††† Neuritic plaque score should be determined by the method of CERAD: Mirra SS, Heyman A, 
McKeel D, et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. 
Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology. 
1991;41(4):479-486.
Resulting scores are then combined to yield an estimate of AD neuropathologic 
change (not, low, intermediate or high), with an estimate of intermediate or high 
required to confirm a clinical diagnosis of AD dementia. These revised guidelines 
additionally incorporate the reporting of neuropathologic findings tied to common 
comorbidities, such as Lewy body disease, vascular brain injury, TDP-43 inclu-
sions and argyrophilic grain disease. 
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1.2.2 Amyloid cascade hypothesis
According to the amyloid cascade hypothesis, AD is caused by the accumulation 
of Aβ in the brain.125-128 Originally based on the mapping of the amyloid precursor 
protein (APP) to chromosome 21,129-132 the observation of AD neuropathology as 
an invariable feature in trisomy 21 (Down syndrome),133 and the linkage of APP 
mutations to cerebral amyloidosis (hereditary cerebral haemorrhage) and familial 
AD,134,135 the amyloid hypothesis has since been revised to include additional lines 
of evidence suggesting that it is soluble oligomeric Aβ, as opposed to monomers 
or insoluble Aβ aggregates, that trigger the disease cascade.136-138 Mechanistically, 
aggregation of Aβ1-42 is thought to lead to tau pathology, neurodegeneration, and 
clinical symptoms. Alternatively, tau pathology may in fact antecede Aβ, develop-
ing in subcortical and medial temporal limbic areas, with Aβ somehow mediating 
its extratemporal spread.139,140 
Certain observations, however, have raised doubts about the validity of the amyloid 
hypothesis. These include the finding of substantial Aβ deposits in asymptomatic 
individuals,141 the finding of amyloid and tau pathology in non-Down’s syndrome 
mentally retarded adults,142 the poor correlation between cognition and the  number 
of Aβ deposits in the brain,143 the failure of anti-amyloid clinical trials,144-146 and the 
recent finding that trisomy of chromosome 21 increases Aβ deposition  independently 
of the additional APP copy.147 Though alternative hypotheses have been proposed, 
including those ascribing a primary role to tau and neuroinfammation,148,149 the 
 amyloid hypothesis thus far possesses the most experimental support and remains 
the dominant explanatory model of AD.  
1.2.3 Cholinergic hypothesis
The cholinergic hypothesis of AD states that the amnestic symptoms seen in AD 
are tied to the progressive disturbance of cholinergic innervation within limbic 
and neocortical brain regions.150 This hypothesis stemmed from three key observa-
tions: that presynaptic cholinergic markers are depleted in the brains of people with 
AD;151,152 the observation that the nucleus basalis of Meynert, located in the basal 
forebrain, and the primary source of cholinergic innervation to the cerebral cortex, 
is heavily affected by neurodegeneration in AD;153,154 and by the demonstration that 
memory performance can be impaired by cholinergic antagonists, and restored by 
cholinergic agonists.155 This hypothesis received compelling validation following 
symptomatic improvement in patients with AD after the use of compounds that 
blocked the breakdown of acetylcholine (acetylcholinesterase inhibitors, AChEIs) 
(Figure 6).156 Shown to improve cognition, global function and activities of daily 
living, as well as some behavioral manifestations in AD,157,158 the use of this drug 
class has since become the prevailing standard in the pharmacotherapeutic manage-
ment of AD.
12
Figure 6. Physiology of the cholinergic synapse. Choline is the critical substrate for 
the synthesis of acetylcholine. Acetyl coenzyme A (Ac CoA), which is produced by the 
breakdown of glucose (carbohydrate) through glycolysis (Krebs cycle), along with the 
enzyme choline acetyltransferase (ChAT) are critical for the synthesis of the neuro-
transmitter acetylcholine (Ach). Once the neurotransmitter acetylcholine (Ach) is released 
into the synapse, it binds (activates) postsynaptic receptors (M1), thus transmitting a 
signal from one  neuron to the other. The excess neurotransmitter in the synaptic cleft is 
broken down by the enzyme acetyl cholines terase (AChE) into choline and acetate, which 
are returned by an uptake mechanism for recycling into Ac CoA. Adapted Hampel H, 
Mesulam MM, Cuello AC, et al. The cholinergic system in the pathophysiology and 
treatment of Alzheimer’s disease. Brain. 2018;141(7):1917-1933. Copyright Oxford 
University Press, 2018.
1.2.4 Neuropsychological assessment 
The purpose of neuropsychological testing in the context of a patient presenting 
with cognitive complaints is to obtain a thorough characterization of the latter. This 
includes establishing whether the impairment is objective in nature, its distribution 
across cognitive domains (e.g. episodic memory, language, visuospatial function), 
and its severity. Often approached in terms of standard deviations below a nor-
mative reference group, impairment is generally considered when performance 
falls 1.5 to 2 units below the reference group mean. In addition to age, norms 
are often corrected for education; this stems from findings showing that in older 
individuals with high education, performance may fall in the normal range despite 
significant cognitive decline.159 This is assumed to reflect high cognitive reserve, 
whereby the brain is able to meet the demands imposed by cognitive testing in a 
more efficient manner.160-162 Some data suggests, however, that estimation of an 
individual’s premorbid intelligence quotient may better capture cognitive reserve 
and is thus a more appropriate correction.163-166 
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Neuropsychological testing in AD has played an important role in the detection of 
early cognitive changes, as well as in the staging and tracking of disease progres-
sion.  Typically, limbic regions subserving memory are the earliest sites affected 
in AD, producing a circumscribed deficit in anterograde episodic memory.63,167-169 
As pathology spreads to involve other neocortical regions, additional cognitive 
domains become affected, including attentional and executive processes, semantic 
memory, praxis and visuospatial abilities.170-176 Of note, atypical presentations of 
AD have been described involving early prominent deficits in non-memory domains, 
including language and visuospatial perception.177 Separation of AD from other 
dementia disorders has been shown possible using cognitive measures;178-182 neuro-
psychological testing, however, is most informative early on in the disease course, 
as the distinctiveness of impairment profiles decreases with clinical progression.183 
Though broad consensus has yet to be reached, a uniform neuropsychological test 
battery has been proposed for use in the evaluation of dementia disorders.183,184 
1.3 BIOMARKERS
A biomarker is an objectively measurable physiological, biochemical, or anatomic 
parameter that can be treated as an indicator of biological processes (normal or 
pathological) or responses to a treatment.140,185 In addition to guiding population 
enrichment and facilitating selection of drug candidates in AD therapeutic trials, 
biomarkers are increasingly used as diagnostic tools, allowing for earlier and more 
accurate identification of AD pathology and as aids in the context of treatment 
decisions.186 In AD, the most established biomarkers can be divided between those 
derived from molecular imaging and CSF. 
1.4 MOLECULAR IMAGING
A biomedical research discipline, molecular imaging encompasses the visualiza-
tion, description, and measurement of biological processes of interest, occurring at 
the cellular and subcellular level, in living subjects.187 Techniques include positron 
emission tomography (PET) and magnetic resonance imaging (MRI). While of 
limited spatial resolution, PET is sensitive to biological processes in the pico-molar 
(10-12) range; MRI, by contrast, has tremendous spatial resolution (sub-millimetre 
range) but lower sensitivity (micro-molar; 10-6). In conjunction, these modalities 
provide critical information on brain physiology and anatomy. 
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1.5 POSITRON EMISSION TOMOGRAPHY
1.5.1 Fundamentals and quantification
1.5.1.1 PET physics 
The key principles underlying PET are summarized in Figure 7. In essence, PET 
records the spatial distribution of a positron emitting radioactive isotope (radio-
isotope) in tissue(s) of interest. The initial step preceding and requisite to the PET 
investigation itself, is the production of a radioisotope. This is generally accom-
plished using a particle accelerator known as a cyclotron; here, a high-energy beam 
is used to bombard a stable isotope. In this way, the target nucleus is rendered 
unstable, yielding the desired radioisotope. The latter is then chemically incorpo-
rated into a molecule of interest (specific to the desired biological target), yielding 
a compound known as a radiopharmaceutical, or PET tracer. Following quality 
control (QC) procedures, the tracer is then injected into the patient or research 
subject. As the radioisotope seeks to regain a more stable atomic composition, it 
undergoes spontaneous decomposition; the product of this process is known as an 
anti-electron, or positron. Once a positron combines with a surrounding electron, 
a process known as annihilation occurs, whereby two photons (gamma rays) of 
511 kiloelectron volts (keV) each are emitted in approximately opposite directions.
Figure 7. Schematic representation of a PET detector ring and the two-step emission 
of γ‑rays following the disintegration of an unstable flourine‑18 atom, yielding stable 
oxygen-18 (A). The distance between the fluorine atom and the annihilation is greatly 
exaggerated. In the rightward panel (B), data is collected in frames during a dynamic 
PET scan over 90 minutes. The graph shows the time-activity curve for the whole brain 
uptake, with higher standard deviations early in the scan due to shorter frames. Adapted 
from Heurling K, Characterization of [18F]flutemetamol binding properties. Doctoral 
thesis, Uppsala University, 2015.
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A PET scanner comprises a cylindrical assembly of block detectors, in a ring 
structure, with a depth of several blocks. The depth of this cylinder is known as 
the field-of-view (FOV), and is the space occupied by a patient or research sub-
ject. Detection of 511 keV coincident photons by scintillation detectors within the 
FOV forms the basis of PET. These detectors, comprised of inorganic crystals, 
emit flashes of light after photon absorption. Following conversion of this signal 
to an electrical pulse and amplification by photo-multiplier tubes, the pulse is 
sorted according to incoming energy and registered as a single event, or count 
(i.e. a pair of photons detected simultaneously). By means of computer-based 
algorithms, detected counts can be reconstructed into images showing the spatial 
distribution of the tracer in units of radioactivity concentration (Bq/mL). These, 
in turn, can be analysed using mathematical approaches to investigate a range of 
outcome parameters. A crucial prerequisite to the reconstruction step is correction 
for several factors, including photon attenuation (due absorption by tissue), ran-
dom events (two unrelated photons are recorded as an event) and dead time loss 
(time during which the scanner detection system is unable to record events due 
a combination of count rate, scintillation decay time, and scanners electronics).
PET acquisition protocols can be divided into dynamic and static approaches. In 
dynamic scanning, data acquisition is started directly upon injection of the tracer, 
and collected over time. This can be performed using either pre-specified intervals 
known as frames (typically of increasing duration), with reconstructed images 
then showing the events detected at each voxel during the specific time period, or 
continuously over time (list-mode). In the case of list-mode acquisition, data can 
then be binned into frames during reconstruction, affording greater flexibility. The 
radioactivity measured in a voxel or brain region during a dynamic scan can be 
summarized by a time activity curve (TAC), showing the behaviour of the tracer 
over time. Static acquisition refers to specifying a single frame over the course of 
the scan; this provides a single image representing the average amount of radio-
activity during the specified interval. Some static protocols, however, incorporate 
a dynamic component, whereby acquisition is performed over several frames fol-
lowing an uptake period. These frames are typically averaged, however, providing 
a static image. Though advantages and disadvantages exist for both approaches,188 
head-to-head comparison has shown dynamic scans to provide higher accuracy, 
reproducibility, and image contrast.189,190
In order to be of value in the quantification of targets in the brain, a PET radio tracer 
must fulfil a range of stringent criteria.191 These include the ability to readily cross 
the blood-brain barrier (BBB), a high affinity (nanomolar (nM) range) towards the 
target, and the absence of radiometabolites passing the BBB that could contaminate 
the recorded PET signal. Additional criteria include selectivity (i.e. low off-target 
binding), favourable pharmacokinetics (rapid brain penetrance and wash-out), high 
specific activity and safe for administration in low doses. Lastly, a PET tracer 
16
should prove amenable to labelling with carbon-11 or fluorine-18; owing to the 
short half-life of carbon-11 (20 min), several PET studies with different tracers can 
be performed in a single day, allowing for the  collection of complementary infor-
mation from a disease characterization standpoint.192 Given the short half-life of 
carbon-11, however, an on-site cyclotron along with specialized infrastructure and 
personnel are required. Tracers labelled with the longer-lived fluorine-18 have thus 
been developed and commercialized for  clinical applications as the longer half-
life (110 min) allows for centralized production and regional distribution, even to 
centres lacking access to the full range of resources required for PET. 
1.5.1.2 Registration and spatial normalisation
Head movement during PET studies is a common occurrence and can degrade 
image quality, producing misalignment between emission and attenuation cor-
rection data and decreased quantification accuracy.193-196 As such, approaches for 
motion correction have been developed that involve the estimation of between-
frame realignment parameters (translations and rotations) that minimize the sum 
of square difference between each frame and a reference image.197 This process of 
image realignment is known as registration, and can also be performed between 
different modality images (co-registration, e.g. PET to MRI) from the same subject. 
This allows for the delineation of brain structures on high resolution T1-weighted 
MR images, and their application to PET in order to sample a parameter of  interest, 
such as the non-displaceable binding potential (BPND), which, for reversibly binding 
tracers, describes the targets available for tracer binding;198 moreover, if PET and 
MR images are co-registered, the PET image can more accurately be mapped onto 
a template image in stereotaxic space (a process known as spatial normalisation),199 
a step that allows for findings to be reported according to a standard coordinate 
system.200-203 Co-registration can also be performed between images stemming 
from the same modality (e.g. longitudinal studies).
1.5.1.3 Approaches to PET quantification
Compartmental models
Following injection, the tracer distributes throughout the body, assuming a number 
of states, including a free fraction in the blood pool, a tissue fraction (unbound, 
specifically bound to the intended target, and non-specifically bound, e.g. to non-
target proteins), and a circulating metabolized fraction. The signal recorded by 
the PET scanner comprises the sum of these physiologically separate tracer pools 
(known as compartments). In order to isolate the parameter of interest (i.e. tracer 
specifically bound), kinetic modelling is applied, whereby the dynamics between 
compartment are described using first order differential equations (compart mental 
modelling).198,204 This allows for the estimation of physiological parameters of 
interest, such as BPND BPND, (ratio between receptor bound and free ligand)198,205 
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or distribution volume (VT, volume occupied by tracer/total tissue volume under 
equilibrium in relation to plasma radioactivity concentration). Requiring arterial 
blood sampling so as to determine the metabolite corrected arterial input function 
(i.e. the unchanged radiotracer in arterial plasma), compartmental modelling is 
regarded as the gold standard in PET quantification.
Reference region models
Due to the invasive and labour-intensive requirements of compartmental  modelling, 
so-called reference tissue models have been developed, whereby arterial plasma is 
replaced by a reference region as the source of the input function.204 This class of 
models assumes that the reference region is free of specific binding (i.e. devoid of 
the target), with kinetics best described by a 1-tissue compartment (1-TC) model, 
whereby only tissue uptake and washout are considered.206-209 These models further 
assume that free tracer and non-specific binding i.e. ratio of influx/efflux (K1 and 
k2) parameters are the same in both target and reference regions. Commonly used 
models include the simplified reference tissue model (SRTM),206 yielding BPND, k2 
(transfer rate constant for tissue to plasma efflux in the target region) and R1 (ratio of 
K1 in target and reference regions) and reference input Logan,210 which provides the 
distribution volume (DVR), defined as ratio of VT in target and  reference regions. 
Semi-quantitative approaches
In order to implement compartmental or reference region models, dynamic data 
acquisition and fairly long scanning durations are required. In contrast, semi-
quantitative estimates can be determined using shorter time-windows, on a frame-
by-frame basis, or using frame summation, which provides an average image over 
a given time-window with improved count statistics. A common approach relates 
the radioactivity concentration in a target region to that within a reference region 
(assuming the above-mentioned assumptions); this gives a standardised uptake 
value ratio (SUVR), which provides an estimate of the relative signal from specific 
(target region) and non-specific (reference region) binding (i.e. activity concentra-
tion in target divided by the reference). In addition to the simplified acquisition 
parameters, SUVR is not affected by potential variability tied to administered 
radioactivity and body size.211 Despite its many advantages, SUVR may vary with 
time if tracer washout varies between target and reference regions;212 as such, the 
time window for estimation of SUVR must be validated. 
Region and voxel-based approaches
Neuroimaging data can be analysed using region-of-interest (ROI) and voxel-
based methods. An ROI (also referred to as volume-of-interest, VOI) broadly 
refers to a set of voxels that have been grouped together on the basis of a particular 
characteristic, such as their probability of belonging to a given anatomical brain 
region.213-216 A good choice when a strong a priori hypothesis exists regarding 
which brain region(s) are involved, ROI based analyses also provide smoother 
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TACs (due averaging of voxels within the ROI), resulting in more robust param-
eter estimates. A drawback, however, is that findings that are constrained to a 
small area within an ROI, or that lie across ROI borders, will be lost. Voxel-wise 
analyses, by contrast, require imaging data to be in a standard coordinate space, 
and use parametric images, whereby a physiological parameter of interest (e.g. 
DVR), as opposed to radioactivity concentration, is represented by the value of 
each voxel. Parametric images will often be spatially smoothed with a filter similar 
in size to the scanner’s resolution, removing spurious voxels and increasing data 
normality and signal-to-noise ratio. While not subject to the limitations of ROI 
based analyses, voxel level TACs have a comparatively higher degree of noise, 
which can affect quantification accuracy.
Partial volume effect
As a result of the relatively poor spatial resolution of PET, the measured concen-
tration of radioactivity in a given voxel reflects different tissue fractions as well as 
contributions from adjacent regions (Figure 8).217 This is referred to as the  partial 
volume effect (PVE), and leads to inaccuracies in radioactivity concentration 
estimates in reconstructed images, and, correspondingly, in derived parametric 
images.217 Several methods have been proposed to correct for this effect,218 includ-
ing MRI driven approaches that rely on segmentation maps (i.e. assigning each 
voxel a tissue class: grey matter (GM), white matter (WM), CSF. In one such 
method, proposed by Müller-Gärtner et al.,219 spill-over between white and grey 
matter compartments can be estimated and accounted for using tissue segmentation 
fractions, providing a GM specific correction. Though adjustment for PVE has 
been proposed to improve quantitative accuracy, methods reliant on anatomical 
information have been shown to be affected by the quality of the segmentation 
and image registration steps.220,221 shown vs proposed.
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Figure 8. Schematic representation 
of the impact of PVE on pixel data. 
Two adjacent pixels with different 
radio activity concentrations (true 
data; A). Due to PVE, the intensity 
of the signal in each pixel spills out 
(B), resulting in a dilution of the signal 
(C). PVE results in a lower measured 
image intensity, as well as an  overlap 
in the signal measured from both 
structures. Adapted from Heurling K, 
Characterization of [18F]flutemetamol 
binding properties. Doctoral thesis, 
Uppsala University, 2015.
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1.5.2 Amyloid imaging
The first study using the carbon-11 ligand Pittsburgh Compound-B ([11C]PIB), 
a thioflavin-T derivative specific for Aβ, showed increased retention in cortical 
areas in AD dementia patients, as compared to controls,222 a finding that has since 
been reproduced in numerous studies.223 The widespread success of [11C]PIB and 
the limitations of carbon-11 prompted the development and commercialisation of 
fluorine-18 labelled compounds for wide availability.224-227 As for [11C]PIB, these 
tracers have as their substrate the tertiary β-pleated sheet conformation of  fibrillar 
amyloid.228 Studies using [11C]PIB and these longer-lived compounds have shown 
that approximately 30% of cognitively unimpaired (CU) elderly225,229-233 and 60% 
of MCI229,234-237 patients show amyloid positivity. These findings match autopsy 
studies showing comparable percentages meeting neuropathological criteria for 
AD.139,236,238-240 Among patients diagnosed as AD dementia, roughly 10% are amy-
loid negative using PET;225,229,230,235,241 given the high correspondence between PET 
and neuropathological assessments,242 these cases are largely assumed to represent 
clinical misdiagnosis.231,243 
Importantly, amyloid PET positivity in CU and MCI subjects is interpreted to rep-
resent AD in its preclinical and prodromal phases, respectively, and is  associated 
with an increased likelihood of abnormal neuro degenerative biomarkers and cog-
nitive decline.244 Emergence of significant Aβ pathology (i.e. amyloid positivity) 
has been suggested to occur for many in their mid-50s;245 Aβ deposition is then 
thought to increase in a slow and continuous fashion, with sigmoidal kinetics over 
time. Specifically, using [11C]PIB, it has been shown to take 12 years to progress 
from mean SUVR levels seen in amyloid negative CU older adults to the threshold 
for positivity, and a further 19 years to reach SUVR values seen in AD dementia 
patients.246 In studies that have looked at the rate of change in amyloid PET as a 
 function of uptake at baseline,246-248 after an initial accumulation phase, a peak is 
reached, followed by a decline to an accumulation rate of nearly zero, implying 
a plateau in amyloid load.247 Though a fairly substantial window of opportunity for 
secondary prevention studies was established based on these studies,247 the consistent 
failure of clinical trials employing anti-amyloid compounds249 suggests that by the 
time brain amyloid deposition has reached a plateau, amyloid may be less relevant 
as a target, with the disease course instead driven by downstream processes.249 
Among the above-mentioned fluorine-18 amyloid tracers, three have been 
approved by both the European Medicines Agency (EMA) and the US Food and 
Drug Administration (FDA), including [18F]AV-45 ([18F]florbetapir; Amyvid),226 
[18F]-BAY94-9172 ([18F]florbetaben; Neuraceq)250 and [18F]3′-F-PIB ([18F]
flutemetamol; Vizamyl),227 (Figure 9) in order to estimate Aβ neuritic plaque 
 burden in cognitively impaired patients who are being investigated for AD and 
related causes of cognitive decline. Currently, these tracers are validated for binary 
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visual reads only, whereby images are rated as positive (abnormal) or negative 
(normal).251,252 Clinical studies using these compounds, while few in number, 
suggest that amyloid imaging can increase diagnostic confidence and alter patient 
management.253-255 Large-scale multi centric US (Imaging Dementia – Evidence for 
Amyloid Scanning; IDEAS) and European studies (Amyloid imaging to prevent 
Alzheimer’s disease; AMYPAD) are also underway, aiming to examine the clini-
cal utility of amyloid PET, including its cost-effectiveness.256
1.5.2.1 Appropriate use criteria for amyloid imaging
In connection with the availability of fluorine-18 amyloid tracers, appropriate 
use criteria (AUC) were published by an Amyloid Imaging Taskforce (AIT) 
assembled by the Nuclear Medicine and Molecular Imaging and the Alzheimer’s 
Association.257,258 Broadly, amyloid imaging was defined as appropriate in patients 
with objective cognitive impairment of unclear aetiology (though with AD as a 
potential diagnosis) and when findings are expected to result in increased diagnostic 
certainty and altered patient management. More specifically, in MCI patients for 
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whom the syndrome is persistent and of unclear aetiology; in patients fulfilling 
core clinical criteria for AD dementia but with an atypical or etiologically mixed 
presentation (i.e. possible AD),259 and in dementia patients with atypical age of 
onset (i.e. below age 65). The application of these criteria is to be performed by 
a dementia expert, defined as a physician with training and board-certification in 
psychiatry, neurology, or geriatric medicine with ≥ 25% of patient contact being 
with adults suffering from cognitive impairment or dementia.258 Similar  consensus 
based practice guidelines have been proposed by the Specialized Task force on 
Amyloid imaging in Canada (STAC)260 and the Society of Nuclear Medicine 
and Molecular Imaging (SNMMI)/ European Association of Nuclear Medicine 
(EANM).261 
1.5.3 Tau imaging
The latest addition to the armamentarium of tools available for the study of neuro-
degenerative disorders, tau imaging has largely emerged from international efforts 
aiming to replicate the success of amyloid PET.262 As a molecular target, tau is chal-
lenging:262 located intracellularly, it can assume six different isoforms; these can 
combine in various ways, and are further subject to post-translational modifications,263 
leading to heterogeneity among ultrastructural conformations (Table 2).264 Further, 
though Aβ and tau deposits are known to co-localize, the concentrations of tau are 
far lower than those for Aβ.265,266 Despite these challenges, remarkable progress has 
been made in the development of tau-selective ligands (Figures 10 and 11), with 
first-generation tracers (namely, [18F]AV1451, [18F]THK5317, [18F]THK5315, and 
[11C]PBB3) widely used in research studies267-271 and second-generation tracers (such 
as, [18F]MK-6240, [18F]RO6958948), [18F]PI2620, and  under development.272-276 
Table 2. Varied tauopathies and their tau isoform characteristics. 
Type Pathology Isoform Light microscope Electron microscope
I Alzheimer’s disease
Down’s syndrome
3R and 4R
3R and 4R
NFTs
NFTs
PHFs and SFs
PHFs and SFs
II Corticobasal 
degeneration
Progressive 
 supranuclear palsy
4R
4R
Astrocytic plaques
Globose tangles; 
tufted astrocytes
SFs and TFs
SFs and TFs
III Pick’s disease 3R Pick’s bodies RCFs and TFs
IV Myotonic dystrophy Short 3R NFTs –
3R, Three repeat tau; 4R, Four repeat tau; NFTs, Neurofibrillary tangles; –, Not available; 
PHF, Paired helical filament; RCF, Random coil filament; SF, Straight filament; TF, Twisted 
 filament. Adapted from Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau 
 imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114-124
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Figure 10. Chemical structures and representative uptake images in amyloid positive AD 
patients using selected first- and second-generation tau PET tracers. For the creation of 
parametric images for all tracers, areas of the cerebellar cortex were used as reference. 
The [18F]AV1451 image is courtesy of the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI); the [18F]RO-948 image is courtesy of Professor Oskar Hansson and the Swedish 
Biomarkers for Identifying Neurodegernative Disorders Early and Reliably (BioFINDER) 
2 study. Though direct comparison is complicated by between-patient differences, one can 
observe the preferential binding of the first- and second-generation tracers in AD relevant 
areas of the temporal lobes, and the broader dynamic range seen with [18F]RO-948. DVR, 
distribution volume ratio; SUVR, standardised uptake value ratio.
Figure 11. Chemical structures of selected second-generation tau PET tracers
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In vitro studies using first-generation tracers showed high binding affinity to and 
specificity for tau aggregates, with high overlap between observed binding patterns 
and tau-immunohistochemistry (e.g. AT8, PHF-1) in AD brain tissue.267,268,270,271,277,278 
Further, early in vivo studies showed tracer retention to be elevated in patients 
with AD, as compared to CU elderly individuals.268,270,279-281 Findings in MCI have 
varied between restricted elevations in medial temporal cortices to neocortical 
binding at a level comparable to AD, likely reflecting between study differences 
in the proportion of amyloid positive subjects.81,82,280,281 Several studies have also 
shown a close correspondence between the pattern of ligand uptake and the known 
distribution of tau pathology based on post-mortem studies.63,238 Combined with 
cross-sectional findings showing tau PET to associate with measures of neuro-
degeneration (hypometabolism; cortical atrophy)271,282,283 and cognition,80,284,285 this 
suggests that tau imaging may be useful in predicting the evolution of AD and/or 
as a marker of disease stage.276,286 Longitudinal findings, however, suggest the lack 
of a linear association between tau pathology and 2-deoxy-2-[18F]fluoro-D-glucose 
([18F]FDG) PET.287 Although the number of publications using second-generation 
tau tracers are to date few and in limited samples,288-290 available findings are con-
sistent with those using first-generation ligands. 
Though the majority of studies with tau imaging have focused on AD, those in 
non-AD tauopathies, such as corticobasal syndrome (CBS) and PSP have shown 
patterns of tracer retention that accord with the expected spatial distribution of 
tau based on neuropathology studies.268,291-294 In vivo studies in PSP have generally 
shown distinct pattern of tracer uptake in subcortical brain regions and the cerebellar 
dentate nuclei.295-298 Comparison of ante- and post-mortem findings in PSP, however, 
has shown that in some patients, there tracer binding was absent in structures show-
ing signal in vivo,299,300 possibly reflecting a low binding affinity of [18F]AV1451 
for 4R tau.276 Further, comparative studies between tau ligands suggest that they 
differ in their sensitivity and specificity toward AD-type PHF tau, highlighting 
both the complexity of tau pathology and the potential need for multiple tracers to 
properly characterize primary tauopathies.301,302 A further limitation of tau imaging 
is the observation of off-target binding to multiple targets, including monoamine 
oxidase A (MAO-A) and B (MAO-B)303-306 this phenomenon, however, appears 
so far reduced or absent in second-generation tracers.273,274
1.5.4 Cerebral glucose metabolism
The primary substrate for energy production in the brain, glucose metabolism has 
been closely tied to neuronal (synaptic) and, more recently, astrocytic, activity.307-310 
Consumption of glucose in the brain can be measured using [18F]FDG, a fluorine-18 
labelled glucose analogue.311,312 Following transport into the brain by the same  carrier 
that transports glucose across the BBB,313 [18F]FDG is  phosphorylated by  hexokinase, 
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yielding [18F]FDG-6-phosphate. Lacking a hydroxyl group, however, this labelled 
product cannot proceed further along the glycolytic pathway,312 becoming trapped 
in the cerebral tissue, at least over the time course of a typical PET study. 
A considerable body of work using [18F]FDG PET has identified a characteristic 
pattern of metabolic changes in clinically established AD (Figure 12).314-317 This 
ensemble includes the posterior cingulate/precuneus, the inferior parietal lobe, 
as well as the posterolateral and medial temporal lobe. Decline in the uptake of 
[18F]FDG within these regions has been shown to associate with clinical progres-
sion across the continuum of AD,318-322 including the emergence of MCI among 
elderly subjects,323,324  and to correlate with the neuropathologic diagnosis of AD 
at autopsy.325,326 Further, distinct spatial patterns of hypometabolism have been 
associated with atypical focal cortical presentations of AD,203,327,328 and have been 
of value in the differentiation of AD from other dementia disorders, including 
frontotemporal dementia (FTD) and dementia with Lewy bodies (DLB).329
Figure 12. [18F]FDG PET scan in a patient with AD dementia; circles indicate areas 
typically showing hypometabolism in AD, including the temporal (TL) and parietal 
(PL) lobes, as well as the precuneus (PC). Involvement of the frontal lobe (FL) can be 
seen later on the disease course, while metabolism within the occipital lobe is typically 
preserved.
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1.5.5 Cerebral blood flow
Though classically measured using PET with oxygen-15 labelled water ([O15]
H2O),330-332 cerebral blood flow (CBF) can also be estimated through the  application 
of reduced configuration models to dynamic PET data.204 Replacing arterial plasma 
with a reference tissue as the source of the input function, such models provide 
perfusion information in the form of the parameter R1 (Figure 13), 206,333,334 shown 
to be highly correlated with regional CBF, as measured by [O15]H2O.335 A related 
measure, perfusion SUVR (p-SUVR), defined as the calculation of SUVR over 
the initial minutes post tracer injection, has also been used as a proxy of CBF 
(Figure 13).336 In contrast to R1, however, this parameter does not require kinetic 
modelling due the assumption that the initial portion of tracer uptake reflects K1,337 
with p-SUVR thus reflecting CBF.
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1.5.5.1 Coupling between cerebral blood flow and glucose metabolism
Blood flow and glucose consumption in the brain have been shown to be closely 
linked under physiological conditions338 and in those with AD and related neuro-
degenerative disorders.317,339 As a result of this linkage, studies have explored 
the use of regional CBF estimates derived from dynamic amyloid PET studies 
as proxies for [18F]FDG metabolic imaging.336,340-343 Additional studies have used 
the dopamine transporter tracer [11C]PE2I,344 and the tau tracers [18F]AV1451345 
and [18F]THK5317.340,346 Overall, these studies have shown that regional perfusion 
estimates correlate strongly with [18F]FDG and may prove of value in the context 
of differential diagnosis between dementia disorders. Some findings suggest, 
however, that conditions may exist under which the parallelism between these 
parameters may become decreased.346-349
1.6 STRUCTURAL BRAIN IMAGING
Information pertaining to the structural (i.e. anatomical) integrity of the brain can be 
obtained using computed tomography (CT) and MRI. CT is a computerized x-ray 
based imaging technique whereby a narrow beam of x-rays is rotated around the 
head, generating tomographic images.350 These can then be digitally concatenated, 
yielding a three-dimensional image of the brain.350 MRI, by contrast, involves 
the use of a strong magnetic field and electromagnetic (radio) waves in order to 
manipulate hydrogen nuclei (protons) within the body; this results in the patient or 
subject being scanned emitting a signal, which can be received and reconstructed 
into an image.351 Given that proton content varies across tissue types, combinations 
(sequences) of radio wave pulses and gradations in the external magnetic field 
of the scanner can be used to modulate the signal from a given tissue class.351 In 
Figure 13. [18F]THK5317 perfusion (p-SUVR and R1) images in a patient with AD 
dementia. Decrements in cerebral blood flow can be seen in temporoparietal (TL, 
 temporal lobe; PL, parietal lobe) and frontal (FL) areas, as well as in the posterior 
 cingulate (PC), a spatial topography similar to that seen with [18F]FDG PET.
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the context of brain imaging, for example, the relative signal from GM, WM and 
CSF can be adjusted, according to what one wishes to examine (e.g. morphology, 
vascular changes, cerebrovascular disease). 
In AD, CT and MRI studies have shown that atrophy typically begins in the entorhinal 
cortex, followed closely by the hippocampus, amygdala, and parahippo campus.352-356 
Volumetric loss then spreads to involve lateral aspects of the temporal lobe, followed 
by neocortical association areas.357-359 This pattern of atrophy progression has been 
shown to closely follow the known spatial distribution of neurodegenerative changes 
in AD from autopsy studies,63,360,361 and to correlate strongly with cognitive decline;362 
as such, atrophy is considered a good marker of disease progression.363 In clinical 
practice, visual rating of medial temporal lobe atrophy is commonly performed in 
specialist memory centres as this measure carries good positive predictive value for 
AD, both in terms of differentiation from normal aging364-366 and identifying MCI 
subjects at risk for progression to dementia.367,368 Visual assessment of additional 
brain areas can further be of help when attempting to discriminate AD from other 
dementia disorders,369,370 and in the recognition of atypical forms of AD where wide 
variation in medial temporal atrophy exists.371,372 
In the context of memory clinics, detection of atrophy (medial temporal, global 
cortical) and WM changes has been shown to be comparable using visual rating 
of images on a newer CT scanner and a 1.5T MRI.373 Though CT carries several 
advantages over MRI,374 including increased availability, more rapid data acquisition, 
lower cost, and the ability to image patients with MR-incompatible ferromagnetic 
objects such as pacemakers, MRI is better able to detect cerebrovascular lesions 
when compared with most currently used CT scanners,375 has higher resolution, and 
lacks ionizing radiation.376 The utility of MRI, moreover, is broader;  in addition to 
a growing interest in the automation of pattern classification,377 additional measures 
of cerebral perfusion,378 integrity of WM fibre pathways,379 brain activation (both 
at rest and in response to tasks),380 and perturbations in brain biochemistry381 are a 
major focus within the field, given the belief that they might be more sensitive than 
anatomic measures to early disease-related changes.382 These measures, however, 
lack validation and as yet are not established for use in clinical practice. 
1.7 CEREBROSPINAL FLUID BIOMARKERS
CSF fills the ventricles and surrounds the brain and the spinal cord. Its functions 
include cushioning the brain against trauma, removal of metabolic by-products 
 generated by the activity of neurons and glial cells, and the circulation of biologically 
active substances within the brain.383 Production of CSF is accomplished largely 
by the choroid plexus, a specialized organ within the lateral, third and fourth ven-
tricles, with the remainder (~10-20%) arising from bulk flow of interstitial fluid 
along perivascular spaces and axonal tracts.384 In adults, the intracranial volume 
of CSF has been estimated at roughly 155 mL; CSF turn-over is high (~0.4 mL/min), 
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with an average of 650 mL produced daily.385-387 Due its direct contact with the 
central nervous system, CSF is considered an ideal source of information for the 
detection and measurement of biochemical abnormalities within the brain paren-
chyma,388 and can be sampled via lumbar puncture (LP), a safe and well-tolerated 
procedure.389-392 Analytes of interest in CSF can then be quantified using a range 
of techniques, including enzyme linked immunosorbent assays (ELISAs), electro-
chemiluminescence, and mass spectrometry (MS). 
1.7.1 Assays
1.7.1.1 Immunoassays
A powerful method for the detection and quantification of selected molecules in 
complex solutions and tissue preparations, the ELISA was first developed in the 
early 1970s393,394 due advances in the production of antigen-specific monoclonal 
antibodies395 and methods to achieve their chemical linkage to biological enzymes 
able to emit a measurable signal.396-398 Although a number of ELISA variants exist, 
all are characterized by the same basic elements: an antigen, one or several antibodies 
specific to that antigen, and a system to quantify the amount of antigen present. 
Given the low abundance of most CSF based proteins,399,400 the capture or sandwich 
ELISA is widely used due its high sensitivity and specificity (Figure 14). First, a 
capture antibody, highly specific for the antigen, is attached to a solid phase (e.g., 
detection plate surface, membranes and beads). The antigen (sample or calibra-
tor) is then added, followed by detection antibody, bound, directly or indirectly, 
to a reporter system (e.g. signal-generating enzyme or fluorophore). For detec-
tion, the appropriate substrate is added, with the observed signal (colorimetric or 
fluorometric) proportional to the amount of antigen in the sample. Simultaneous 
quantification of multiple analytes (multiplexing) can also be performed using the 
xMAP Luminex401 and Meso Scale Discovery (MSD) platforms;402 these rely on 
bead-based technology (capture antibodies coupled to dyed beads or microspheres 
with varied emission spectra) and an electrochemiluminescent label conjugated 
to the detection antibody, respectively. 
Figure 14. A schematic diagram illustrating a sandwich ELISA. 
Using sandwich assays, the analyte of interest (blue sphere) is 
measured using two antibodies: a capture antibody (bottom) and a 
detection antibody (top), coupled to a reporter system (star symbol; 
e.g. horse radish peroxidase). Following addition of a substrate 
(e.g. p-Nitrophenyl-phosphate), a signal (colorimetric or fluoro-
metric) is emitted in proportion to the amount of target antigen in 
the sample. Adapted with permission from Landegren U, Al-Amin RA, 
Bjorkesten J. A myopic perspective on the future of protein diagnos-
tics. N Biotechnol. 2018; 45:14-18. Copyright Elsevier, 2018.
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In contrast to traditional analogue ELISA systems, in which the intensity of the 
detection signal increases as a function of analyte concentration, digital ELISA 
allows for the measurement of individual molecules.403-405 This technique has 
recently been extended to a bead-based approach that uses an arrangement of 
femtoliter-sized reaction chambers termed single-molecule arrays (Simoa).406 Using 
this ultrasensitive method, single molecule immunocomplexes can be detected, 
with sample and reagent volumes, cost, and analysis times below those for con-
ventional immunoassays.407
1.7.1.2 Mass spectrometry based quantification
MS is an antibody-independent analytical technique used to determine the molecular 
composition of a compound.408 The first step in a mass spectrometric analysis is the 
transformation of the sample into an ionized gas; these ions are then accelerated 
through the use of electric and/or magnetic fields, and, following fragmentation, 
are separated according to their mass-to-charge (m/z) ratio. Detected in proportion 
to their abundance, a mass spectrum (relative ion abundance against m/z; ordinate 
and abscissa, respectively) is thus produced. MS can also be performed in parallel 
(MS/MS), allowing for analysis of an analyte and its fragments.
Within clinical laboratory medicine, reference measurement procedures (RMPs) 
and certified reference materials (CRMs) are considered the gold standards for CSF 
measurements.409-413 Defined as a method producing metrologically traceable results 
that can be linked to an established higher-order standard (i.e. the International 
System of Units) through a chain of unbroken comparisons, an RMP can be used 
to assign or verify the concentration of a CRM (with a known concentration in SI 
units) for the analyte of interest, which can subsequently be distributed for assay 
calibration. Establishment of a CRM can be achieved using an MS based RMP 
known as selected reaction monitoring (SRM) (Figure 15).414 In this approach, solid 
phase extraction (SPE) and liquid chromatography (LC) are included prior to the 
MS step in order to concentrate and extract, respectively, the desired analyte.415 
MS/MS is then used to increase selectivity, with quantification of the endogenous 
analyte possible through comparison of its signal to that of a stable isotopically 
labelled internal standard.414,416
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1.7.2 Standardisation efforts
Though commercial assays for AD biomarkers (Aβ1-42, p-tau181p, and t-tau) show 
similar diagnostic accuracy in the separation of AD patients from those with related 
neurodegenerative diseases or controls,286,401 reported analyte concentrations have 
been shown to vary significantly.417 This is thought to reflect the sensitivity of 
these assays to pre-analytical (e.g. sample handling and storage),418-422 analytical 
(e.g. between/within differences in laboratory procedures),423,424 and assay-related 
(e.g. manufacturing based variations in the analytical kit components) factors.418,424 
As a result of differences in absolute concentrations, different cut-offs have been 
used between centres, complicating clinical practice and comparability in single 
and multicentre studies.425 International efforts to standardise CSF procedures are 
currently ongoing, however,426 including a QC program monitoring within and 
between laboratory measurement variability.417,427,428 In a step towards the imple-
mentation of universal cut-off levels, SRM MS-based RMPs have been published 
for Aβ1-42;429 these methods will be used to establish CRMs that can then be used 
for assay calibration by manufacturers.409,426
Figure 15. Selected reaction monitoring (SRM) mode on a triple quadrupole mass 
spectrometer. SRM is a targeted mass spectrometry based analysis involving the use 
of a triple quadrupole mass spectrometer comprising three consecutive quadrupole 
mass analysers. The first quadrupole is set to transmit a precursor ion based on its 
mass-to-charge (m/z) ratio. In the second quadrupole, which is filled with an inert 
gas such as argon or nitrogen, collision induced dissociation is then used to fragment 
this ion as it collides with the gas molecules. The third quadrupole is set to transmit 
one or more specific product ions generated in the second quadrupole to the detector. 
SRM greatly increases selectivity compared to single ion monitoring, since interfering 
ions with  identical m/z co-isolated in the first quadrupole will most likely not give rise to 
 product ions with identical m/z to that of the analyte of interest. Adapted from Pannee J, 
Mass spectrometric quantification of amyloid-beta in cerebrospinal fluid and plasma. 
Doctoral thesis, University of Gothenburg, 2015.
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1.7.3 Amyloid-β pathology
The precursor to Aβ, the APP is a transmembrane protein comprising a large 
extracellular N-terminal region and a lesser intracellular tail.430 Two pathways 
exist for the degradation of APP: in the nonamyloidogenic pathway (so-called due 
it precluding the generation of Aβ), APP is cleaved within the Aβ domain by the 
protease α-secretase, resulting in the production of an 83-amino acid C-terminal 
fragment (C83) and a soluble APP (α-sAPP) fragment. C83 is subsequently cleaved 
by γ-secretase, yielding a truncated peptide (Aβ17-32, or p3). This fragment, how-
ever, has been found in senile plaques431 and may possess neurotoxic properties,432 
suggesting that the pathway moniker may be somewhat of a misnomer. In the 
amyloidogenic pathway, APP is by contrast cleaved by β-secretase, producing a 
large N-terminal fragment (β-sAPP) and an intracellular 83-amino acid C-terminal 
fragment (C99); in a second step, C99 is cleaved by γ-secretase, releasing Aβ 
 peptides. Among these, Aβ1-40 has been shown to be the most predominant variant, 
followed by Aβ1-38 and Aβ1-42.433
Initial studies examining CSF Aβ did not differentiate between isoforms (i.e. total 
Aβ). Though some studies found a slight decrease in this measure in AD,434-436 
large overlap was observed in comparison to controls, with other studies finding 
no change.437-439 Following the discovery of multiple C-terminal forms of Aβ, and 
the observation that the 42-amino acid isoform was highly aggregation prone440 
and predominant in diffuse and senile plaques,441,442 ELISAs specific to Aβ1-42 
were developed.438,443 Using this method, a marked reduction in Aβ1-42 was found 
in AD dementia patients438,444 with levels shown to correlate inversely with cortical 
plaque load in AD brain tissue in both post-mortem445,446 and biopsy studies.447 
Reduced Aβ1-42 has been hypothesized to reflect the preferential deposition of 
Aβ1-42 in plaques, resulting in a reduction in the amount available for passage into 
the CSF.438,448,449 Reduced CSF Aβ1-42 has also been observed in disorders without 
plaques, however, including amyotrophic lateral sclerosis450 and CJD,451 suggesting 
the involvement of additional mechanisms. 
The high abundance of Aβ1-40 in CSF,452 combined with its lower potential for 
aggregation,453 suggests that its levels can theoretically provide a better index of 
amyloidogenic APP processing, in comparison to Aβ1-38 or Aβ1-42. Moreover, the use 
of Aβ1-40 in ratio with Aβ1-42 (Aβ1-42/ Aβ1-40) has been proposed as a method to adjust 
for interindividual differences in Aβ production levels.433,454 Indeed, some studies 
have shown improved discrimination between AD and non-AD disorders using this 
measure,454-456 as well as improved power to predict AD in subjects with MCI.457 
1.7.4 Tau pathology
The identification of Aβ as the main component in plaques,458,459 and the subse-
quent cloning of APP,129 occurred nearly in parallel to the discovery that tangles 
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were composed of abnormally hyperphosphorylated tau.77 Though multiple phos-
phorylation sites exist on the tau protein,460 the most commonly used assays for 
phosphorylated tau (p-tau) use antibodies targeting phosphorylation at threonine 
181 (p-tau181) or 231 (p-tau231).461,462 Studies using these measures have consist-
ently shown an increase in p-tau in AD;463 these subtypes of p-tau have further 
been shown to strongly correlate and exhibit similar diagnostic performance.464 
In addition to p-tau, levels of total tau (t-tau), determined using monoclonal anti-
bodies able to detect all tau isoforms, independent of their phosphorylation state,465 
have also been shown to be markedly increased in AD.466-468 Elevations in both 
measures have been shown to correlate with more rapid progression from MCI to 
AD, the rate of hippocampal atrophy,469 and faster cognitive decline in AD.470-473 
Though positive correlations have been reported between CSF tau (p-tau, t-tau) 
and neocortical tangle burden at autopsy,445,447,474-477 associations for p-tau appear to 
be specific to threonine 231;474,475 p-tau231 may, further, have greater sensitivity for 
NFTs as it been shown to detect tau pathology in layer II of the entorhinal  cortex, an 
area considered to be the earliest site affected by tangles in AD.478 Current  thinking, 
however, suggests that p-tau may best reflect the phosphorylation state of tau in 
the brain, which, in turn, is related to the development of tangle pathology, as 
opposed to the burden of tangles per se.424 While the level of t-tau may partially 
reflect the release of tau from degenerating neurons affected by tangle pathology, 
its marked elevation in acute disorders such as stroke and brain trauma479-481 and 
conditions characterized by rapid neurodegeneration (e.g. CJD)482 suggests that 
it primarily reflects the intensity of neuronal injury and degeneration.424 Indeed, 
CSF t-tau is considered as such a marker in the recently proposed AD biomarker 
classification scheme (see “A/T/N”, section 1.11).483,484
1.7.5 Neurodegeneration
A key feature of AD pathophysiology, the degeneration and loss of synapses has 
been shown to more strongly correlate with cognitive deficits in AD than either 
Aβ plaque or tangle load.87,485 The hypothesis that synaptic markers might thus 
show a strong association to cognition in AD led to the identification of several 
synaptic proteins in CSF, including neurogranin.91,486 A postsynaptic dendritic pro-
tein highly expressed by excitatory neurons in the cortex and hippocampus,487,488 
neurogranin has been shown to play a key role in synaptic plasticity and induction 
of long-term potentiation.489,490 High CSF levels have been observed in AD491-
494 and have further been shown to correlate with both the rate of hippocampal 
atrophy and extent of metabolic reduction on [18F]FDG PET.495 Moreover, high 
CSF neurogranin seems to be specific to AD, as this finding was absent among 
patients with a range of other neurodegenerative disorders.496 A further measure, 
neurofilament light (NFL), a marker of large-caliber axonal degeneration, has also 
been shown to be increased in MCI and AD, and to associate with structural brain 
changes and cognitive decline.497 
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1.8 RELATIONSHIP BETWEEN PET AND CSF 
BIOMARKERS
Following the first study showing an inverse association between global cortical 
retention of [11C]PIB and CSF Aβ1-42498 have numerous publications since confirmed 
this finding.234,499-504 Across these studies, approximately 90% of subjects showed con-
cordance between amyloid biomarkers (i.e. both abnormal or normal), with discord-
ant cases divided nearly equally between isolated low CSF Aβ1-42 and isolated PET 
positivity.505 Investigation of discordant cases has shown biomarker disagreement 
to vary by disease stage, with isolated CSF Aβ1-42  positivity highest in CU elderly, 
intermediate in MCI and lowest in AD dementia.244 Further, CSF Aβ1-42 was found 
to more strongly relate to carriage of the apolipoprotein E (APOE) ε4 allele, with 
amyloid PET, by contrast, showing the strongest relationship to CSF tau (p-tau181p 
and t-tau) levels and cognitive decline. This was interpreted as indicating that CSF 
Aβ1-42 may be more sensitive to early Aβ pathology, with amyloid PET, by contrast, 
more sensitive to disease progression.244 Though it has been proposed that fibrillar 
Aβ may be detectable prior to declines in CSF Aβ1-42,501 isolated amyloid PET posi-
tivity may in fact better relate to the use of cut-offs for Aβ1-42 that are in fact too low 
and to false negative results tied to high Aβ production levels.
For tau imaging, a modest positive correlation has been reported between [18F]
AV1451 uptake in CU older adults, patients with AD and non-AD neurodegenerative 
disorders, including PSP and FTD, and CSF tau (p-tau181p and t-tau).506-509 Though 
agreement between biomarkers was generally greater in AD dementia, in compari-
son to preclinical and prodromal stages, overall concordance rates reached 70%.508 
In a related study examining the diagnostic performance of these markers,510 CSF 
tau and [18F]AV1451 uptake exhibited comparable performance in prodromal AD; 
[18F]AV1451, however, showed superior performance in the dementia stage of AD. 
These findings, combined with studies showing early plateauing of CSF tau511-513 
and increases in tau PET signal in AD,285,506,507 suggest that CSF tau may behave as 
disease state markers, reflecting the intensity of the AD process, with tau imaging, 
by contrast, best described as a stage marker, reflecting disease progression.286,514 
In the one study that has to date examined tau biomarkers in non-AD subjects, 
[18F]AV1451 and CSF tau showed similar performance in differentiating non-AD 
from Aβ-positive AD patients, suggesting that these measures are largely reflec-
tive of AD-type PHF tau.509 In light of recent findings showing that a range of tau 
fragments exist in CSF, with these characterized by differing kinetics,515,516 and 
a stronger relationship between such fragments and tau imaging (e.g. theronine 
205 an 207, as compared to 181, with [18F]GTP1 PET)),517 novel measures may 
be required in order to achieve optimal concordance with tau imaging. Previous 
studies addressing the relationship between CSF tau and cross-sectional [18F]
FDG PET in AD have shown inconsistent results for both p-tau181p and t-tau.518-522
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1.9 RECOMMENDATIONS FOR THE DIAGNOSTIC USE 
OF CSF AD BIOMARKERS
Recently, international multidisciplinary based recommendations were proposed for 
the clinical implementation of CSF AD biomarkers (Aβ1-42, p-tau181p and t-tau) in the 
diagnostic evaluation of patients with MCI and dementia.523,524 According to their 
interpretation scheme, positive Aβ1-42 and tau markers indicate that MCI is likely 
due to AD. This pattern in dementia patients increases the probability that AD is 
the underlying cause; as such, AChEIs or memantine (an NMDA glutamate receptor 
antagonist) and nonpharmacological treatments should be offered. Abnormal Aβ1-
42 and normal tau should be followed by examining CSF cell count/albumin and 
cut-offs, sample reanalysis and/or inclusion of other imaging biomarkers. In cases 
with normal Aβ1-42 / abnormal tau, non-AD neurodegenerative disorders should be 
considered and additional biomarkers, such as Aβ1-40 or imaging based measures, 
added. In patients with normal CSF biomarkers, other medical conditions such as 
depression should be considered. 
Given the high variability commonly seen with CSF biomarker measurements (up 
to 10%), fairly broad gray (border) zones exist,525 complicating binary  classification; 
in such cases, sample reanalysis is recommended. Importantly, however, both sets of 
recommendations emphasized that the current evidence base surrounding the choice 
of AD biomarkers (CSF or imaging) was conflictual or insufficient, highlighting 
the need for further studies. Strong support for the use of CSF in conjunction with 
clinical measures was only reported for the prediction of functional/cognitive 
decline in MCI, and to rule out AD as the underlying aetiology in patients with 
mild dementia. Novel fully automated instruments, showing high precision and low 
variability across lots and laboratories, have however been developed;526 their use, 
alongside standardisation efforts, including those addressing preanalytical  sample 
handling procedures, should result in the wider use of Aβ1-42 CSF measurements 
in routine clinical practice; similar progress for CSF tau will be made in the near 
future. This, combined with the growing use of fluorine-18 amyloid PET (and likely, 
soon, tau) ligands will generate the data required to refine current recommendations.
1.10 DIAGNOSTIC ASSESSMENT OF COGNITIVE 
IMPAIRMENT
An important tool in directing the use of evidence-based practice in the diagnosis 
and management of dementia disorders, clinical practice guidelines have been 
advanced by guideline development groups, including the European Federation 
of Neurological Sciences.527 Intended to optimize patient care, these recommen-
dations are developed by a multidisciplinary panel of experts and are guided by 
a systematic evidence review.528
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In Sweden, national guidelines have been developed addressing the clinical handling 
of patients presenting to health care professionals due to cognitive impairment.529 
According to these, a detailed history of the presenting complaints is taken from 
the patient and their spouse or close family member; in addition, brief cognitive 
tests are administered (e.g. the Mini-Mental State Examination (MMSE),530 and 
Clock-Drawing Test,531 assessing global cognition and visuospatial/executive func-
tion, respectively). Physical, neurological, and psychiatric examinations are also 
performed, in addition to blood work, functional assessment (the patient’s ability 
to perform activities of daily living),532 and structural brain imaging with either 
CT or MRI. In the event of uncertainty following this first-level assessment, or if 
the patient is below age 65, a referral for a more expanded work-up is undertaken; 
this may include detailed testing by a neuropsychologist and/or speech pathologist, 
CSF sampling, and PET based investigations (glucose metabolism and/or amyloid).
1.11 REVISED RESEARCH DIAGNOSTIC CRITERIA 
FOR AD
Though widely used in clinical research and therapeutic trials, the original 
NINCDS-ADRDA criteria have recently been revised in order to incorporate 
advances made along clinical, biological, and conceptual lines. These revisions, 
initiated by an International Working Group (IWG-1 and 2)41-43,533 and the National 
Institute on Aging and the Alzheimer’s Association (NIA-AA),44,46,259,534 include 
the recognition of nonamnestic presentations of AD,535-537 and the incorporation 
of biomarkers of the underlying disease process; a distinction between clinical 
expressions of AD pathophysiology was also drawn, with the resulting recogni-
tion of preclinical (accrual of AD pathology in the absence of symptoms) and 
 symptomatic pre-dementia (prodromal AD or MCI due to AD) states.
Despite their similarities, these criteria differ somewhat in their overall approach 
and terminology, as well as in their application of cognitive and biological mark-
ers.538,539 The IWG-1 criteria, for instance, require impairment in episodic memory 
and at least one biomarker supportive of AD (e.g. temporo-parietal hypometabolism 
on [18F]FDG PET, CSF showing decreased Aβ1-42 and elevated tau, or a positive 
amyloid PET scan) for a diagnosis of prodromal AD;42 in contrast, cognitive 
impairment can be in any cognitive domain in the IWG-2 criteria, supported by 
either CSF (decreased Aβ1-42 and increased tau) or amyloid PET.43 According to the 
NIA-AA criteria for MCI due to AD,44 cognitive impairment need not be memory 
based, with biomarker abnormalities required for amyloid (decreased CSF Aβ1-42 
or positive amyloid PET) or neuronal injury (medial temporal atrophy on MRI, 
increased CSF tau, or [18F]FDG hypometabolism), with the number of abnormal 
biomarkers (both, one, none) translating into an estimate of the likelihood that the 
observed MCI syndrome is due to AD.
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In a recent multicentre study in patients with MCI, the IWG-1, IWG-2, and 
NIA-AA criteria were compared with respect to the proportion of subjects fulfilling 
criteria for prodromal AD/MCI due to AD and the rate of conversion to AD-type 
dementia.539 Though performing similarly in a broad sense, findings showed that 
the proportion of MCI classified as prodromal AD was greater using IWG-1 criteria, 
while IWG-2 and NIA-AA criteria showed somewhat better performance at pre-
dicting progression to AD dementia. Despite comparable accuracy in predicting 
cognitive decline, this study indicates that one set of criteria may be favoured over 
another depending on the setting and availability of biomarkers:539,540 in clinical 
trials, for instance, where a high rate of conversion is needed, IWG-2 prodromal 
AD or those fulfilling the NIA-AA high AD likelihood criteria would be best (i.e. 
any MCI, assuming availability of biomarkers for amyloid and neuronal injury). 
If only neuronal injury biomarkers are available, the IWG-1 criteria should, by 
contrast, be considered due its higher specificity tied to the requirement of an 
amnestic MCI phenotype. In clinical settings, where a more refined prognosis is 
required, the NIA-AA criteria, with its broad definition of MCI, may provide the 
most accurate prognosis. 
Based on the scientific advances made since the 2011 NIA-AA diagnostic criteria 
for AD,44,46,259,534 a biomarker focused research framework was recently proposed 
to unify and update initial recommendations.483 This framework incorporates the 
so-called “A/T/N” system,484 in which biomarkers can be grouped into those for 
amyloid-β (A; elevated amyloid PET or low CSF Aβ1-42 or Aβ1-42/ Aβ1-40), abnormal 
tau (T; elevated tau PET or CSF phosphorylated tau (p-tau)), and neurodegeneration 
(N; hypometabolism on [18F]FDG PET, atrophy on MRI, or elevated CSF total tau 
(t-tau)). In defining a given individual’s biomarker (A/T/N) profile, either CSF 
or imaging biomarkers can be used alone or in combination (e.g. CSF Aβ1-42 and 
P-tau for A and T, respectively, and MRI as N). According to this framework, AD 
is no longer regarded as three clinically distinct entities (preclinical, MCI, AD) 
but rather as a continuum, with whether or not an individual is in this continuum 
defined using biomarkers (e.g. AD, A+/T+/N- or A+/T+/N+) (Figure 16). These 
biomarker profiles can be combined with two different cognitive staging schemes; 
the first involves traditional syndromic labels and is applicable to all biomarker 
profiles (i.e. AD and non-AD), while the second six-stage numeric scheme applies 
only to those in the AD continuum. 
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1.12 TIME COURSE OF ALZHEIMER’S DISEASE 
On the basis of cross-sectional autopsy and biomarker data, a hypothetical order-
ing of changes in AD biomarkers and clinical disease phases was proposed in 
2010 by Jack and colleagues.541 In this model, Aβ dyshomeostasis is considered 
a triggering event, upstream to hyperphosphorylation of tau, neurodegeneration 
and cognitive impairment. As such, Aβ biomarkers (CSF Aβ1-42 and amyloid PET) 
were considered to become abnormal first, followed by neurodegenerative bio-
markers (CSF tau, [18F]FDG PET, and structural MRI). The model incorporated 
biomarker abnormalities in CU individuals, with cognitive decline (i.e. the onset 
and progression of symptoms) closely tied to the extent and rate of change in 
neurodegenerative biomarkers.362,542,543 Importantly, biomarker trajectories were 
viewed as following a non-linear temporal course, likely sigmoidal in shape.544,545 
Figure 16. Hypothetical time course of Alzheimer’s disease. AD neuropathological 
changes are thought to precede symptom onset by some 20-30 years; this process can 
be detected with current recognized biomarkers. Importantly, the relationship between 
a given individual’s cognitive status and biomarker profile is thought to be influenced 
by risk factors, including genetic risk alleles, cognitive reserve (the brain’s ability to 
compensate for pathology), and comorbid brain pathologies. The grey zones on the left-
ward end of the bars for amyloid and tau are in acknowledgement of the fact that it has 
yet to be definitively established whether amyloid precedes tau pathology, with medial 
temporal tau potentially preceding amyloid. The prospective (X) bar is in recognition 
of the fact with we will likely learn a great deal from new and upcoming biomarkers 
for targets such as α-synuclein, TDP-43, and the synaptic vesicle protein 2A. Colour 
scales indicate theoretical changes over time. Adapted with permission from Silverberg 
N, Elliott C, Ryan L, Masliah E, Hodes R. NIA commentary on the NIA-AA Research 
Framework: Towards a biological definition of Alzheimer’s disease. Alzheimers Dement. 
2018;14(4):576-578. Copyright Elsevier, 2018. 
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Widely accepted by the research community, a revised version of the model was 
proposed in 2013,546 incorporating slight changes in the ordering and shape of 
biomarker trajectories, as well as the concept of low and high risk for cognitive 
impairment due to AD pathophysiology (due genetic profile, cognitive reserve, 
lifestyle factors and comorbid brain pathologies). This model also acknowledged 
findings suggesting that in many individuals, a subcortical tauopathy may be the 
earliest pathophysiological process in AD; Aβ pathology is thought to then emerge 
later and independently, yet to synergistically accelerate this pre-existing tauopathy, 
leading to the neocortical spread of tangle pathology.139,547 
A number of additional models have also been described; similar to the model 
originally proposed by Jack et al., these too incorporated AD biomarkers on the 
ordinate and clinical stages on the abscissa.548-551 Of these, two have incorporated 
neuroinflammation (astrocytosis and/or microglial activation),548,550 as well as oligo-
meric forms of Aβ and disruptions in cholinergic neurotransmission.548 More 
recently, curves relating CSF tau to tau PET imaging were derived from subjects 
with autosomal dominant AD, with changes in the former preceding changes in 
the latter,551 similar to the ordering proposed for Aβ biomarkers.552,553
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2 AIMS
The overarching aim of this thesis was to gain new insight into how different 
PET and CSF based functional and molecular measures interrelate in AD, and 
to examine their potential utility from a clinical standpoint. Study specific aims 
were as follows:
In paper I, to compare concordance between [11C]PIB PET and CSF Aβ1-42 in 
a multicentric cohort, using historical and centrally reanalysed CSF measures; 
Aβ1-42/ Aβ1-40 was also included to examine its effect on agreement levels with 
[11C]PIB PET.
In paper II, to examine the impact of amyloid imaging with [18F]flutemetamol 
PET on diagnostic decision making and treatment management in tertiary memory 
clinic patients with an unclear diagnosis. 
In paper III, to investigate the association between [18F]THK5317 retention and 
CSF tau, using assays for both classical and novel fragments, in a cohort of patients 
with AD (prodromal and dementia).
In paper IV, to explore the potential use of [18F]THK5317 perfusion parameters 
(p-SUVR and R1) as proxies for metabolic imaging with [18F]FDG PET in patients 
in the prodromal and dementia stages of AD. 
In paper V, to determine the reproducibility of [18F]THK5317 perfusion parameters 
as well as their longitudinal relationship to [18F]FDG and tau pathology in patients 
from study IV who underwent follow-up investigations.
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3 PARTICIPANTS AND METHODS
3.1 PARTICIPANTS
3.1.1 Paper I
The study cohort comprised 243 subjects (230 patients and 13 CU older controls) 
from seven European memory clinics belonging to BIOMARKAPD (Biomarkers 
for Alzheimer’s and Parkinson’s Disease),554 a research program aiming to optimize 
and standardise the collection, analysis and interpretation of biomarkers in AD and 
PD.524 All had [11C]PIB PET and historical CSF Aβ1-42 data available, as well as 
aliquots of CSF available for reanalysis. Patients had been referred on the basis of 
cognitive complaints and assessed clinically according to standard local routines. 
All diagnoses (AD, n=122; MCI, n=81; FTD, n=20; vascular dementia (VaD), 
n=7) were made according to standard criteria,30,45,555,556 using a consensus-based 
multidisciplinary approach, including neurologists, clinical neuropsychologists, 
specialist nurses, psychiatrists, and speech-language therapists.557 CU controls 
were recruited from among relatives and patient care givers. Inclusion criteria were: 
the absence cognitive complaints, independence in activities of daily living, and 
normal neurological and psychiatric examinations.
3.1.2 Paper II
207 patients were included from the Clinic for Cognitive Disorders, Theme Aging, 
Karolinska University Hospital, Stockholm, Sweden. Referral sources included 
primary care physicians as well as other hospital clinics. Following diagnostic 
workup, including medical and neurological examination, clinical rating batteries 
for depression and neuropsychiatric symptoms, neuropsychological assessment, 
structural imaging, and, in a subset, CSF analyses (Aβ1-42, p-tau181p, t-tau; n=152), 
and [18F]FDG PET (n=76), the clinical picture remained unclear. Diagnoses were 
made prior to and following [18F]flutemetamol PET, according to standard diag-
nostic criteria,3,18,30,45,555,556,558 and followed a multidisciplinary consensus based 
approach. 
3.1.3 Papers III-IV
Twenty patients were recruited from the Clinic for Cognitive Disorders, Theme 
Aging, Karolinska University Hospital, Stockholm, Sweden. All had completed 
a comprehensive battery of investigations, including a detailed history taking, 
physical examination, routine blood work, cognitive and neuropsychological test-
ing, CSF sampling, and structural imaging. Patients diagnosed as prodromal AD 
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(n = 11) and AD dementia (n = 9) fulfilled classical criteria for MCI and prob-
able AD, respectively, and, in addition, showed in vivo evidence of Aβ pathology 
(abnormal [11C]PIB). 
The number of patients per study varied, however. Fourteen patients, evenly divided 
between prodromal and dementia groups, were included in study III, including ten 
(6 prodromal, 4 dementia) with follow-up data; in this study, the limiting factor was 
the availability of CSF for reanalysis. Study III also included nine CU individuals 
(THK-controls: five young, four elderly: 20-30 and 58-71 years old, respectively), 
recruited through Clinical Trial Consultants AB (Uppsala University Hospital, 
Uppsala, Sweden) or from patients’ relatives as part of an earlier study;280 all were 
free from medication and non-smokers, completed extensive clinical evaluations, 
and were included in the absence of known neurological/ psychiatric disorders, 
head injury, or cognitive complaints. A further 15 individuals were included 
from the Sahlgrenska University Hospital as CSF negative controls; these were 
patients with minor cognitive complaints, where basic (cell count, albumin ratio, 
IgG index) and core (Aβ1-42/Aβ1-40, p-tau181p, and t-tau) CSF biomarkers fell within 
normal ranges. In contrast to study IV (n=20), study V included only 16 patients 
(10 prodromal, six dementia) due this being the number for which longitudinal 
[18F]FDG and [18F]THK5317 had been performed. One patient with CBS, recruited 
as part of the initial study describing our findings with [18F]THK5317,280 was also 
included in the test-retest component of study V. 
3.2 COMPLIANCE WITH ETHICAL AND REGULATORY 
STANDARDS
Prior to participation in the above described studies, all participants and their 
care givers provided written informed consent prior. These were performed in 
 accordance with the Declaration of Helsinki and subsequent revisions. All studies 
were approved by the Regional Ethical Review Board in Stockholm, Sweden, and 
the Radiation Safety committees at the Karolinska University Hospital, Stockholm, 
Sweden and the Uppsala University Hospital, Uppsala, Sweden. Ethical approval 
had been obtained from local ethics committees in the case of study I. The CSF 
samples from CSF-controls included in study III were de-identified left-over 
 aliquots from clinical routine analyses, following a procedure approved by the 
Ethics Committee at University of Gothenburg (EPN 140811).
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3.3 IMAGING DATA ACQUISITION AND PROCESSING
3.3.1 Paper I
In this study, [11C]PIB PET data was pooled from seven European research cen-
tres, where scanning platforms and protocols differed: 0-60 min (Coimbra and 
Lisbon, Portugal; Karolinska, Sweden, using Philips PET/CT Gemini GXL and 
Siemens EXACT HR + scanners, respectively); 40-60 min (Ulm, Germany; 
Siemens Biograph mCT Flow); 40-70 min (Copenhagen, Denmark; GE PET/CT 
Lightspeed, Siemens Biograph PET/CT, Siemens PET/MRI, and Siemens ECAT 
HRRT); 50-70 min (Barcelona, Spain; Siemens EXACT HR +); and 60-90 min 
(Turku, Finland; GE Advance PET scanner). 
Dynamic [11C]PIB studies were first corrected for subject motion using a rigid 
realignment procedure between frames (VOIager, version 4.0.7, GE Healthcare 
Ltd., Uppsala, Sweden).559 Summation images (40-60, 40-70, 50-70, and 60-90 
min) were then created in VOIager, and images spatially normalised to a population 
based [11C]PIB template,560 using the Normalise function in Statistical Parametric 
Mapping, version 8 (SPM8). Partial volume correction was not performed due to 
the inclusion of visual ratings previously performed on non-partial volume  corrected 
summation images and between centre differences in scanner resolution. 
3.3.2 Paper II
PET investigations were performed at the department of Medical Radiation Physics 
and Nuclear Medicine Imaging, Karolinska University Hospital, Stockholm, 
Sweden, using a Siemens/CTI Biograph mCT PET/CT. For [18F]flutemetamol, 
the acquisition protocol consisted of a 20 min scan (list-mode), 90 min post 
injection of 185 MBq. Static 15-min [18F]FDG studies were performed 30-min 
after an intravenous bolus injection of 3 MBq/kg. All appropriate corrections, 
including time-of-flight (TOF), were applied, with a low dose CT scan used for 
attenuation correction. Reconstruction was done with ordered subset expectation 
 maximisation (OSEM; 5 iterations, 21 subsets, 2.0 mm Gaussian filter), yielding 
an effective resolution of 3 mm. Structural T1-weighted MRI was performed at 
various radiology departments in Stockholm and neighbouring counties, using 
different platforms and protocols.
Dynamic late-phase (90-110 min) [18F]flutemetamol data was processed using 
a fully automated software under commercial development (Hermes Medical 
Solutions, Stockholm).561A PET driven approach, images were first realigned, 
summed over the 90-110 min interval, and spatially normalised into Montreal 
Neurology Institute (MNI)-152 stereotaxic space. Similar to study I, partial volume 
correction was not performed due the inclusion of visual ratings performed on 
uncorrected summation images.
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3.3.3 Papers III-IV
Patients in studies III-V underwent amyloid ([11C]PIB), tau ([18F]THK5317), and 
metabolic ([18F]FDG) PET imaging within a short time period (median (days), inter-
quartile range (IQR): [11C]PIB to [18F]THK5317: 0 [0, 7]; [18F]FDG to [18F]THK5317: 
58 [40, 80]); 16 patients (10 prodromal AD and six AD dementia), underwent 
follow-up [18F]THK5317 and [18F]FDG PET investigations after a median period 
of 17 months IQR: 15, 18] (studies III-IV). Dynamic (0-60 min) [18F]THK5317 
and [11C]PIB scans were acquired on an Siemens/CTI ECAT EXACT HR+ scanner 
(n=16) or a GE Discovery ST PET/CT scanner (n=4) at the Uppsala PET Centre. 
Static (30-45 min) [18F]FDG PET studies were performed on a Siemens Biograph 
mCT PET/CT scanner at the department of Medical Radiation Physics and Nuclear 
Medicine Imaging, Karolinska University Hospital, Stockholm, Sweden. Test-retest 
[18F]THK5317 data was collected in a subset of five patients (four prodromal AD, 
one CBS), within 22 days [IQR: 13, 27].
Structural (T1-weighted) MR scans were available for all subjects (10 performed 
same day as [18F]THK5317, eight before, two after), and were used for  anatomical 
co-registration and ROI definition; the median interval between MRI and [18F]
THK5317 PET was 32 days [IQR: 0, 509]. MR scans were performed on three 
different platforms, at three different sites: Karolinska University Hospital, 
Stockholm (Siemens Magneton Symphony 1.5T, n=9); Uppsala PET Centre 
(Siemens Magneton Trio 3T, n=8); and Aleris Röntgen Sabbatsberg, Stockholm 
(Philips Diamond Select Achieva 1.5T, n=3). For controls, structural MRI data 
was also collected (eight at Uppsala PET Centre, one with an earlier acquisition at 
Aleris Röntgen Sabbatsberg,) in addition to [18F]THK5317 PET (ECAT EXACT 
HR+, n=6; GE Discovery ST PET/CT, n=3); elderly controls also performed [11C]
PIB PET studies to rule out Aβ pathology. 
Individual dynamic ([18F]THK5317 and [11C]PIB) and static ([18F]FDG) PET scans 
were co-registered to their respective T1-MR images using PMOD (v.3.5; PMOD 
Technologies Ltd., Zurich, Switzerland). Structural images were segmented into 
tissue classes (GM, WM and CSF) using SPM8, with the inverse transformation 
matrix used to spatially warp a probabilistic atlas214 from into native T1 image 
space. GM masks generated during the segmentation step were then applied to 
the atlas subject-wise, yielding individual GM VOIs.
In study III, [18F]THK5317 data was first partial volume corrected in PMOD, using 
the Müller-Gärtner method.219 Here, the focus on how CSF biomarkers related to 
[18F]TH5317 DVR within regions of interest motivated the application of a correction 
method (Müller-Gärtner),219 given the known effects of partial volume, particu-
larly in medial temporal regions.280 In studies IV and V, where [18F]TH5317 was 
also used, correction for partial volume effects was not applied due the focus on 
perfusion information and, in the case of study V, the fact that the Müller-Gärtner 
correction induces spatial distortions when applied at the voxel level.563,564 
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3.4 PET QUANTIFICATION
3.4.1 Paper I
Spatially normalised [11C]PIB summation images were multiplied by a set of 
anatomically defined GM VOIs, previously derived from the multiplication of a 
standard digital atlas216 with an averaged eroded gray matter mask.560 SUVR images 
were then created over the various time windows, using the cerebellar cortex as 
reference tissue, and resulting parametric maps sampled to obtain VOI uptake 
values. In order to obtain a global measure of Aβ burden, a composite neocortical 
[11C]PIB value was calculated as the voxel-weighted average SUVR across frontal, 
parietal, temporal, occipital, and cingulate cortices. An abnormal [11C]PIB scan 
was then defined as a composite SUVR above 1.41 (upper 95% confidence limit 
in CU age-matched controls).560
Due to the variability in scanning windows between centres and the known impact 
of this on SUVR,212 composite neocortical SUVR values were standardised to a 
100-point scale using a linear scaling procedure.565 The units of this scale are termed 
“Centiloids”, with 0 representing the average [11C]PIB uptake in Aβ negative 
subjects and 100, the average in mild-to-moderate AD when scanned 50- to 70- 
min. As per the outlined process, we first validated our pipeline using a publically 
available data set ([11C]PIB and matching T1 MR images from 34 Aβ-negative 
young controls and 45 Aβ-positive AD patients) (Figure 17). Then, using average 
SUVR values from a subset of this data set with imaging up to 90-min, specific 
parameters for the provided conversion equations were estimated, and composite 
neocortical [11C]PIB values for all subjects, as well as the cut-off of 1.41, were 
converted to Centiloid values (Figure 17).
3.4.2 Paper II
[18F]Flutemetamol SUVR was calculated using an isocortical composite region, 
comprising brain areas known to typically display a high burden of Aβ, including 
the frontal, lateral temporal, cingulate, and parietal cortices. The pons was used 
as the reference region. 
3.4.3 Paper III
Reference Logan DVR and SUVR were calculated voxel-wise using partial  volume 
corrected [18F]THK5317 (30-60 min, cerebellar cortex) and [18F]FDG (30-45 min, 
pons) scans, respectively. In addition to the GM VOIs used in studies IV and V, two 
composite regions based on Braak stages for tau pathology were included:63 limbic 
(stage III/IV), comprising the hippocampus, amygdala, parahippocampus and fusi-
form gyri, anterior and middle/inferior temporal cortex, orbital and straight gyri, 
cuneus and temporo-parietal carrefour; and isocortical (stages V/VI), comprising 
all cortical regions save the pre- and postcentral gyri.280
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3.4.4 Papers IV-V
Parametric p-SUVR and SRTM R1 ([18F]THK5317 and [11C]PIB), reference Logan 
DVR ([18F]THK5317, 30-60 min) and SUVR ([18F]FDG, 30-45 min) maps were 
created in PMOD, using the cerebellar cortex as reference region. In contrast to 
study III, where the pons was used as reference region for [18F]FDG SUVR, the 
cerebellum was chosen in studies IV and V in order to ensure a common reference 
region across parameters. Selection of time intervals for p-SUVR were based on 
correlation analyses with R1 and [18F]FDG SUVR.566 In order to obtain VOI based 
values, parametric images were sampled using individual GM atlases; in study V, 
however, R1 values were obtained via kinetic modelling (SRTM) of regional time-
Figure 17. Overview of the conversion of [11C]PIB data to the Centiloid scale. Conversion 
of [11C]PIB SUVR findings to Centiloid (CL) units was carried out in a two-step process. 
First, a level-1 analysis was performed in order to set the “typical” 0- and 100-anchor 
points for all future scaling operations. These correspond to average uptake levels in rela-
tively young amyloid negative subjects (YC-0) and typical AD patients (AD-100), respec-
tively. To do this, [11C]PIB data was downloaded from the Global Alzheimer’s Association 
Information Network (GAAIN) website and processed (SUVR) using a cor tical composite 
(CTX) meta-region and the whole cerebellum (WC) as reference region. After  validation 
of our pipeline via comparison of calculated (CL equation) and  reference CL values ( linear 
regression; scatterplot), the level-2 analysis (required when an approach other than 50- to 
70-min SUVR using CTX and WC VOIs is used) was performed owing to varied scanning 
windows across centres. Conversion of SUVR data (example shown for 40-60 min) and 
our cut-off was then  performed using provided equations. Klunk WE, Koeppe RA, Price 
JC, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation 
by PET. Alzheimers Dement. 2015;11(1):1-15 e11-14.
Level-1 analysis Level-2 analysis
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activity curves. Examined VOIs were largely identical to those used in study IV: 
frontal, parietal, temporal (medial and lateral), occipital, and posterior cingulate 
cortices, with a neocortical meta-VOI encompassing all regions save the medial 
temporal lobe. 
3.5 CSF SAMPLING AND ANALYSES
CSF analyses were included in studies I, II, and III. CSF had been collected via 
LP (~ 10 mL) and stored in polypropylene tubes. After discarding the first 0.5 mL, 
 samples were centrifuged and stored at -80 °C in 1mL aliquots. All CSF samples were 
analysed at the Clinical Neurochemistry Laboratory at the Sahlgrenska University 
Hospital, Mölndal, Sweden; historical values from study I were determined locally. 
3.5.1 Enzyme linked immunosorbent assays
In studies I, II, and III, commercial INNOTEST ELISAs from Fujirebio (Ghent, 
Belgium) were used for Aβ1-42,419 p-tau181p462 and t-tau,465 using the following 
monoclonal capture/detection antibodies: 21F12/3D6, HT7/AT270, AT120/HT7 
and BT2, respectively.567 All analyses were performed according to kit inserts. In 
study III, two additional in-house ELISAs (University of Gothenburg) were used: 
1) for neurogranin, using NG22 (mouse monoclonal in-house antibody) and bio-
tinylated NG2 (mouse monoclonal in-house antibody) as coating and primary 
antibodies, respectively, with enhanced streptavidin-HRP complex (Kem En Tech 
#4740N) for detection and recombinant neurogranin full-length protein-GST as 
calibrator; 2) for tau N-Mid, using Tau12 (Nordic Biosite, binding region aa9-18) 
and a combination of biotinylated HT7 (Thermo Scientific, aa159-163) and BT2 
(Thermo Scientific, aa194-198) as coating and primary antibodies, respectively, 
with an enhanced streptavidin-HRP complex for detection and full-length recom-
binant Tau 441 2N4R (rPeptide) as calibrator. 
3.5.2 Electrochemiluminescence assay
The MSD (Gaithersburg, Maryland, USA) triplex assay was used in studies I and 
III, providing levels of Aβ1-42, Aβ1-40, and Aβ1-38 (V-PLEX, Aβ Peptide Panel 1 
(6E10) Kit).568 This assay uses capture antibodies specific to each Aβ peptide, with 
the n-terminal, anti-Aβ (1-16) antibody (6E10 clone) as the detection antibody.
3.5.3 Mass spectrometry assay
LC-MS/MS was used in study I (Aβ1-42, Aβ1-40, and Aβ1-38). For calibration and 
sample preparation, native (unlabelled) and 15N uniformly labelled Aβ1-40 and Aβ1-42 
and 13C uniformly labelled Aβ1-42 (rPeptide) were prepared as described elsewhere, 
aliquoted, and stored at -80 °C. Preparation of artificial CSF and calibration samples 
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for Aβ1-42 were prepared according to previously established methods.429,569 For 
Aβ1-40, artificial CSF was spiked to a final concentration of 1.5, 5, 10, 20, 30 and 
40 ng/mL native Aβ1-40, with a constant concentration of 15N-Aβ1-40 at 1600 pg/ml 
used as internal standard. Unknown samples (180 μL) were spiked with 20 μL 
internal standard to a final concentration of 1600 pg/mL, 13C-Aβ1-42 and 15N-Aβ1-40. 
SPE and LC, as well as the processing and analysis of MS data, were performed 
as described elsewhere.429
3.5.4 Single molecule array assay
Tau-368 was measured through a Simoa HD-1 analyzer (Simoa, Quanterix, 
Lexington, MA, USA) using magnetic beads conjugated with capture antibody 
anti-Tau368,570 using the conjugation protocol provided by the manufacturer. As 
detection antibody, biotin-labeled KJ9A (Sigma) was used, with series diluted tau 
1-368 recombinant protein570 used as calibrator. 
3.6 DETERMINATION OF BIOMARKER CUT-OFFS
In the present thesis, cut-offs were used in studies I, II, and III. In study I, the cut-
off for [11C]PIB Centiloids (34) was based on the upper 95% confidence interval 
of a group of CU elderly controls (global SUVR > 1.41).560 For historical CSF 
Aβ1-42 derived from the INNOTEST assay , a pre-existing cut-point was selected 
based on the Youden index (sum of sensitivity and specificity – 1)571 that best 
predicted amyloid PET positivity.503 Mixture modelling, whereby an expectation 
maximization algorithm is used to cluster individuals according to their probability 
of belonging to a given group (here, normal and abnormal CSF Aβ1-42 or Aβ1-42/
Aβ1-40),572 was used to generate cutpoints for the additional MSD and MS-RMP 
measurements (Figure 18). In study III, cut-offs for regional [18F]THK5317 were 
determined using the mean plus two standard deviations of the DVR values among 
controls; in study II, the cut-off for isocortical composite [18F]flutemetamol SUVR 
had been previously established in a subset of subjects from a phase II study573 
using the value that provided the best discrimination between AD and controls. 
Similar approaches were used for CSF INNOTEST measures (Aβ1-42, p-tau181p 
and t-tau) in studies II and III, and for tau N-Mid and tau-368/t-tau in study III. 
3.7 STATISTICAL ANALYSES
Between group comparisons were performed using Kruskal-Wallis ANOVA for 
continuous variables; Mann Whitney U-tests were performed post-hoc where 
appropriate. Chi-square or Fisher’s exact test were used for categorical variables. 
Analysis of imaging data was performed at both the ROI and voxel-based level, 
as discussed below. Significance for group level comparisons was generally set as 
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p < 0.05 (two-sided, uncorrected); in studies I and IV, however, false discovery rate 
(FDR) and Bonferroni corrected (correlations) p-values were reported, respectively. 
Statistical analyses were performed using different versions of the software R 
(R Foundation for Statistical Computing, Vienna Austria, http://www.R-project.org/).
3.7.1 Region of interest-based analyses
To investigate the relationship between PET and CSF based measures, linear and 
nonparametric rank-based estimation multilinear regression models were used; in 
the latter models, 2-way interactions were assessed using simple slopes analyses. 
Longitudinal change in PET, as well as longitudinal associations between pairs of 
regional PET measures, were assessed using linear mixed models. Associations 
between PET measures were also investigated using bivariate and partial Pearson 
correlation analyses. Differences between bivariate correlations using Williams’ 
modification of Hotelling’s t-test. The ability of different PET measures to dis-
criminate between patient groups was assessed using receiver operating charac-
teristic (ROC) analyses. Agreement between visual assessment as well as between 
visual read and semi-quantitative values was achieved using percentage agreement 
and Fleiss’ kappa, with diagnostic and treatment change assessed using 1-sample 
proportions test. 
Figure 18. Mixture modelling derived frequency density plots of MSD and MS-RMP 
based CSF Aβ42 and Aβ42/Aβ40 measurements from BIOMARKAPD. The dashed lines 
represent the cut‑offs for CSF Aβ positivity. 
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3.7.2 Voxel-based analyses
Correlation analyses between PET measures were performed using Biological 
Parametric Mapping (v. 3.3), an SPM based toolbox. Annual percentage change 
images were created subject-wise as follows: [(Follow-up - Baseline)/ Baseline]/ 
Time interval between scans (years) x 100%; after averaging individual images, 
binarisation (masking) was performed using the isocortical composite repeatability 
(test-retest) of [18F]THK5317 perfusion parameters. All voxel-based analyses were 
performed in MATLAB 2015a (The MathWorks, Inc., Natick, Massachusetts, 
USA). 
51
4 RESULTS AND REFLECTIONS
4.1 MAIN FINDINGS
4.1.1 Paper I – PET and CSF based amyloid biomarkers
4.1.1.1 Concordance between [11C]PIB and CSF Aβ1-42 
Using the combined sample, agreement between dichotomized [11C]PIB (Centiloid) 
and CSF Aβ1-42 was 73% (INNOTEST), 77% (MSD) and 76% (MS-RMP) (Figure 
19). These figures were lower than reported concordance rates, which averaged 
88% 505 across 10 studies;234,499-502,518,574-577 this was likely due to differences in study 
design and sample composition. In contrast to these studies, which were either 
single centre234,499,500,574,575,577 or based on data from highly selected convenience 
samples,501,502,518,576,578 ours was a multicentre study drawn from several tertiary 
memory clinics showing variable concordance figures (range, 55% to 97%). The 
centres with the lowest concordance (i.e. 55% and 67%) were those which had 
most of the non-AD patients, the group showing the most disagreement between 
amyloid biomarkers. When excluding these centres, overall concordance was 87%. 
The low concordance we observed within this group in comparison to the high 
agreement reported in one of these studies577 can likely be traced to differences 
in the non-AD subtypes included and the finding that CSF Aβ1-42 levels can vary 
markedly in these disorders.580
One of the aims of this study was to see whether concordance would be improved 
by reanalysing CSF batch-wise in one laboratory; this was based on findings 
showing that ELISA derived CSF Aβ1-42 measurements are sensitive to a number 
of factors, including how the samples are handled and stored, choice of calibrator 
peptide, and kit lot.417 Though the overall concordance rates using reanalysed data 
were not substantially higher than that achieved using historical Aβ1-42 (Figure 20), 
this was again driven by continued low-concordance in the non-AD group, and, to 
some degree, by an increase in discordance among CU subjects. Only in the AD 
group was concordance consistently higher using reanalysed data. Though the shift, 
among AD and a subset of CU cases, from largely borderline positive findings to 
clearly lowered values may reflect, for example, the removal of variability tied 
to differing kit lots, the use of different assays complicates direct comparison.418 
All groups, however, showed improved concordance when using Aβ1-42/Aβ1-40 
(Figure 20); this effect was greatest among FTD and VaD patients. This result sug-
gested that, in addition to adjusting for interindividual differences in Aβ  production, 
Aβ1-42 in ratio with Aβ1-40 might also help differentiate true amyloid positive case 
(an isolated drop in Aβ1-42, specific to AD) from conditions characterized by a 
general decrease in Aβ isoforms.581,582 
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Figure 19. Scatterplots reflecting concordance between [11C]PIB Centiloids and CSF Aβ. 
(A) MSD Aβ42 (cut‑off < 515 pg/mL). (B) MSD Aβ42/40 (cut‑off < 0.72); (C) MS‑RMP 
Aβ42 (cut‑off < 896 pg/mL), and (D) MS‑RMP Aβ42/40 (cut‑off < 0.76). Grey circles 
indicate cognitively normal healthy control (CN) subjects, triangles indicate mild cognitive 
impairment (MCI), squares Alzheimer’s disease (AD), crosses frontotemporal dementia 
(FTD), and crossed squares vascular dementia (VaD) patients. The vertical lines reflect 
the Centiloid cut-off of 34; the horizontal lines the cut-offs of 515 pg/mL, 0.72, 896 pg/mL, 
and 0.76 for MSD (Aβ42, Aβ42/40) and MS‑RMP (Aβ42, Aβ42/40), respectively. Blue 
indicates [11C]PIB scans visually rated as negative, red as positive. The grey quadrants 
indicate concordance between amyloid biomarkers (top left, concordant negative: [11C]
PIB‑/ CSF Aβ‑; bottom right, concordant positive: [11C]PIB+/ CSF Aβ+). The white 
quadrants indicate discordance between amyloid biomarkers (bottom left, discordant with 
isolated CSF positivity: [11C]PIB‑/ CSF Aβ+; top right, discordant with isolated [11C]PIB 
positivity: [11C]PIB+/ CSF Aβ‑). Adapted from Leuzy A, Chiotis K, Hasselbalch SG, et al. 
Pittsburgh compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre 
European memory clinic study. Brain. 2016;139(Pt 9):2540-2553.
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4.1.1.2 Agreement between visual and Centiloid-based [11C]PIB classification 
Overall, agreement between visual assessment and Centiloid based classifica-
tion was seen in 235 of 243 [11C]PIB scans (97%) (Figure 19). Among the eight 
instances of disagreement, two were classified as visually negative/Centiloid posi-
tive (one CU and one MCI), and six as visually positive/Centiloid negative (four 
MCI, two AD). Interpretation of the visually negative/Centiloid positive cases 
was complicated by poor image quality and high spill over from WM; all classi-
fied as visually positive/Centiloid negative showed borderline Centiloid values. 
Taking visual ratings as the standard of truth, however, these findings showed that 
the Centiloid method could be successfully implemented in precisely the type of 
context it was developed for.565
Figure 20. Frequency plots showing different agreement profiles between [11C]PIB PET 
and CSF Aβ. Cut‑offs of < 557 pg/mL (INNOTEST Aβ42), < 515 pg/mL (MSD Aβ42), 
< 0.72 (MSD Aβ42/40), < 896 pg/mL (MS‑RMP Aβ42), < 0.76 (MS‑RMP Aβ42/40), and 
global ([11C]PIB Centiloid value > 34 were used to classify subjects as concordant posi-
tive ([11C]PIB+ /CSF Aβ+), concordant negative ([11C]PIB‑/CSF Aβ‑), discordant with 
CSF positivity ([11C]PIB‑/CSF Aβ+), and discordant with [11C]PIB positivity ([11C]
PIB+/CSF Aβ‑). Adapted from Leuzy A, Chiotis K, Hasselbalch SG, et al. Pittsburgh 
compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre European 
memory clinic study. Brain. 2016;139(Pt 9):2540-2553.
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4.1.1.3 Cut-off selection for Centiloid and CSF based classification
As described in section 3.7, the Centiloid cut-point (34) used was based on a global 
SUVR of 1.41, previously established in CU individuals using our image process-
ing pipeline;560 by comparison, other available cut-offs for Centiloid (27.48 and 19) 
were derived from SUVR values of 1.40 and 1.42, respectively, generated using 
post-mortem data (27.48) and a method whereby the selected threshold was based 
on that which reliably predicted an increased rate of change in [11C]PIB SUVR 
(19).583 Back calculation of these CL cut-offs to SUVR using our processing pipeline 
gave values of 1.38 (27.48) and 1.21 (19), illustrating the impact differing methods 
can have on SUVR estimation, and the attendant importance of standardisation in 
settings involving the use of varied acquisition and processing protocols. 
The use of different cut-offs also raises an important point pertaining to the selec-
tion of appropriate thresholds for the detection of biologically meaningful signal 
using amyloid PET.584-586 Though measurements of between 1.40 and 1.50 SUVR 
are routinely used to define amyloid status, these thresholds may be too high, 
misclassifying subjects with substantial plaque pathology as amyloid negative.584 
In our material, isolated abnormal CSF Aβ1-42 was the more common discordance 
profile; while low Aβ1-42 can be seen in the absence of amyloid plaques,450 amyloid 
can also be seen as a co-pathology in non-AD disorders.587 This raises the possi-
bility that the applied cut-off for [11C]PIB was too conservative, which may have 
resulted in the misclassification of at least a subset of these discordant cases. Lastly, 
our use of Gaussian mixture modelling to establish cut-points for CSF measures 
assumed that Aβ1-42 and Aβ1-42/ Aβ1-40 data were composed of two different normal 
distributions.502,572 Although this assumption was valid in our cohort, these cut-
points may not generalize to population-based samples, where unimodal frequency 
distributions have been reported for amyloid biomarkers.583 
4.1.2 Paper II – Clinical impact of [18F]flutemetamol PET 
in a memory clinic setting
4.1.2.1 Structural imaging, [18F]FDG and CSF based investigations
Most of the patients were relatively young (mean age < 65 years), with the majority 
showing a diagnosis of MCI (n=131, 63%), followed by AD (n=41, 20%),  dementia 
not otherwise specified (dementia NOS) (n=20, 10%), non-AD (n=10, 5%) and 
SCD (n=5, 2%). With respect to rating of the temporal lobe, no atrophy or only 
minimal widening of the choroid fissure was predominant across MCI, AD, demen-
tia NOS and SCD; mild atrophy, however, was noted in nearly half of those in the 
non-AD group. In terms of global atrophy and WM changes, most patients showed 
scores consistent with mild changes. Of the 76 patients who underwent [18F]FDG 
PET, patterns suggestive of, but not typical for, AD were the most common  finding 
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in MCI and AD (39% and 56% respectively), with findings in dementia NOS nearly 
evenly divided between atypical for AD and non-AD. In the non-AD group, half 
of patients showed a metabolic pattern suggestive of a non-AD disorder; the other 
half, along with SCD patients, showed only nonspecific changes. 
CSF sampling was not performed in a little over a quarter of patients (n=55, 27%) 
due to use of anticoagulants (n=18, 33%), spinal stenosis or related  problems 
(n=6, 10%), LP refusal (n=12, 22%), and technical problems (n=19, 35%). Of 
the 154 subjects from whom CSF was successfully sampled, 24% showed only 
abnormal CSF Aβ1-42, 23% only abnormal tau (p-tau181p or t-tau), 21% abnormal 
Aβ1-42 in combination with abnormal tau, and 32% showed a negative CSF profile 
(Aβ1-42 and tau above and below cut-offs, respectively). Overall agreement between 
CSF biomarkers and [18F]flutemetamol PET was 66% for Aβ1-42, 66%, 76% for 
p-tau181p, 76% and 77% for t-tau; across all three measures, isolated PET positivity 
was the more the more common discordance profile. Preanalytical (e.g. specimen 
shipment/storage) and assay related factors may have impacted CSF findings, and, 
consequently, concordance with [18F]flutemetamol. Additional possibilities include 
the young age of our cohort (average age 64 years, with 58% fulfilling criteria 
for an early onset dementia disorder, i.e. onset < 65 years), which may have been 
associated with not yet fully distinguished biomarker profiles,580 and  heterogeneity 
in the underlying neuropathology and associated differences in amyloid meta-
bolism and neurodegenerative mechanisms.588 Though disagreement between Aβ 
biomarkers may relate to the cut-point used for CSF, application of a more lenient 
value (647 pg/mL) derived using the same INNOTEST assay provided the same 
overall level of concordance. 
4.1.2.2 Referral for [18F]flutemetamol PET
As noted above, 55 patients were referred for [18F]flutemetamol PET as CSF 
biomarker data was not available. Among those with CSF findings available, the 
main reason for [18F]flutemetamol PET in our cohort was a negative or unclear 
(isolated Aβ1-42 or tau) CSF profile in the context of suspected AD based on clini-
cal, neuropsychological and imaging (CT/MRI, [18F]FDG PET) findings (117 of 
152 patients with CSF; 77%). A clinically unclear picture in combination with 
suspected AD and a supportive CSF profile (low Aβ1-42 and one or both tau markers 
positive), was the second most common reason (35 of 152 patients, 23%). 
4.1.2.3 Change in diagnosis and patient management following  
[18F]flutemetamol PET 
Following visual evaluation of [18F]flutemetamol scans, amyloid positivity was 
found in 69/131 (53%) of patients with MCI as their initial diagnosis, 28/41 AD 
(68%), 2/10 non-AD (20%), 4/20 dementia NOS (20%) and 3/5 SCD (60%). 
Representative [18F]flutemetamol summation images are shown in Figure 21. 
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Amyloid status in the diagnostic groups before and after [18F]flutemetamol investi-
gations, as well as changes in diagnosis, are summarised in Figure 22. As shown in 
this figure, a majority of patients with a final diagnosis of MCI after [18F]flutemeta-
mol PET were amyloid negative. The vast majority of patients in the pre-[18F]
flutemetamol PET MCI group who were amyloid positive received a diagnosis 
of prodromal AD or AD (54 of 60, 90 %).  In the pre-[18F]flutemetamol PET AD 
group, the diagnosis of AD was dismissed in 5 amyloid negative cases. Finally, 
all patients in the pre-[18F]flutemetamol dementia NOS group, and almost all in 
patients in the non-AD group, were amyloid negative. Overall, [18F]flutemetamol 
PET led to a significant change in diagnosis (n=92, 44%; p < 0.05). Among MCI, 
dementia NOS, AD, and non-AD, the highest percentage change in diagnosis 
was observed in the MCI group (n=67, 5 %), as well as in dementia NOS (n=12 
%), while a smaller percent change was seen in non-AD and AD patients (n=3, 
30% and n=8, 20%, respectively). In the SCD group, which only consisted of five 
patients (3 amyloid positive and 2 negative), initial diagnoses were changed in 
three patients (MCI, prodromal AD, and AD). 
The outcome of [18F]flutemetamol PET resulted not only in changes to initial diag-
noses but also in an increase in the use of AChEIs (p < 0.001). Among patients 
with a pre-[18F]flutemetamol diagnosis of MCI, AChEI use increased from nine to 
62 patients, and in AD, from 22 to 38. Among dementia NOS, non-AD and SCD 
patients, AChEIs were initiated in only a handful of patients who had a positive 
Figure 21. Representative [18F]flutemetamol PET summation images in two patients 
initially diagnosed as MCI. The first patient (top row) had a positive scan, the second 
patient (bottom row), a negative scan. Both showed inconclusive CSF, MRI and [18F]
FDG biomarker findings; the first patient received a post-[18F]flutemetamol diagnosis 
of prodromal AD; the second patient, FTD. Scan classification is based on the identi-
fication of high cortical uptake in several brain regions (black circles), as outlined in 
the electronic training programme designed by the manufacturer of [18F]flutemetamol, 
GE Healthcare, Buckley CJ, Sherwin PF, Smith AP, Wolber J, Weick SM, Brooks DJ. 
Validation of an electronic image reader training programme for interpretation of [18F]
flutemetamol beta-amyloid PET brain images. Nucl Med Commun. 2017;38(3):234-241. 
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[18F]flutemetamol scan. Among those in whom treatment was initiated following 
[18F]flutemetamol (n=75), most had a positive scan (n=69) and a final diagnosis 
of AD (n=67; additional diagnoses included three MCI and one DLB; the six [18F]
flutemetamol negative cases included two patients with a post-scan diagnosis of 
AD, two of MCI, one FTD and one DLB). Among the 34 on AChEIs prior to 
[18F]flutemetamol, most were [18F]flutemetamol positive (n=24) and had a final 
diagnosis of AD; ten, however, were [18F]flutemetamol negative and did not have 
AD as a final diagnosis. In one case, an amyloid negative MCI, treatment was 
discontinued following [18F]flutemetamol due to cholinergic side effects. 
4.1.3 Paper III – CSF tau in relation to [18F]THK5317 and 
[18F]FDG
4.1.3.1 Relationship between baseline PET measures and CSF tau 
Associations between CSF tau and baseline PET measures ([18F]THK5317 and 
[18F]FDG) are summarized in Figure 23. P-tau181p related to baseline [18F]THK5317 
uptake within lateral temporal and parietal cortices, as well within isocortical 
composite and Braak V/VI ROIs. By contrast, t-tau related only to isocortical 
composite [18F]THK5317 DVR. Tau-368 related to [18F]THK5317 uptake within 
Figure 22. Diagnostic groups along with visual ratings for [18F]flutemetamol scans before 
and after [18F]flutemetamol PET. Stacked bar charts showing diagnoses before (A) and after 
(B) [18F]flutemetamol investigations; the number of patients per group are indicated at the 
top of each bar. Red and blue indicate visual ratings  of positive and negative, respectively.
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lateral temporal, frontal, isocortical and Braak III/IV ROIs; Tau-368 in ratio to 
t-tau associated significantly to parietal [18F]THK5317 uptake, with tau-368/tau 
N-Mid relating to temporal, posterior cingulate, and occipital [18F]THK5317 DVR. 
Since p-tau181p and tau-368 are thought to reflect, respectively, a pathologic state 
associated with the development of tangle pathology,483 with tau-368 reflecting an 
expansion in the pool of C-terminal fragments that make up PHF tau.570 It would 
thus be expected that these two measures would parallel one another, and perhaps 
show regional overlap with tau-368 ratios, measures thought to provide an estimate 
of tangle pathology. Though regional overlap between these measures was limited 
to the lateral temporal and parietal cortices, as well as more broadly, across all 
cortical regions combined, the associations that emerged as significant at baseline 
involved areas affected in later Braak stages,63,124 in support of this idea. Further, 
recent findings suggest that the development of tangle pathology may not adhere 
precisely to the Braak staging scheme.84,589
Figure 23. Scatter plots showing the relationship between baseline [18F]THK5317 DVR 
and CSF tau-368 (A) and between baseline [18F]FDG SUVR and tau N-Mid (B). For 
[18F]THK5317, though overall fits were negative, an interaction between effect was seen 
whereby positive slopes were observed in those with an isocortical [18F]FDG SUVR > 1.4, 
with negative slopes seen in those with [18F]FDG SUVR < 1.4. Findings from multilinear 
regression analyses are summarized in the chord diagram (C), with each band indicating a 
significant relationship. MTL, medial temporal; LTL, lateral temporal; FRT, frontal; PAR, 
parietal; PCC, posterior cingulate; OCC, occipital; CTX, isocortical composite; LIMB, 
Braak III/IV; ISOC, Braak V/VI. 
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Group level (all subjects combined) regression fits between baseline [18F]THK5317 
and CSF tau were negative; though this finding conflicted with previous studies, which 
showed positive associations between CSF and PET,506,507,509,510,514,590 an interaction 
effect was found whereby [18F]THK5317 and CSF tau were positively associated in 
subjects with more preserved  isocortical glucose metabolism ([18F]FDG SUVR > 1.4); 
those with more impaired glucose metabolism ([18F]FDG SUVR < 1.4) showed a 
negative association, similar to the observed group level fit. With respect to the 
inverse association seen in those with more impaired metabolism, several studies 
suggest that following initial increases, p-tau181p and t-tau may decrease in AD 
with symptomatic progression,591-594 possibly reflecting a deceleration in neuro-
degeneration and/or a reduction in the number of viable neurons releasing tau 
and the sequestration of p-tau in NFTs. Though certain studies have shown little 
to no change in CSF tau longitudinally,595-599 511-513,595-598,600-608 others have shown 
decreases in tau in those with high baseline concentrations591,593,594,596,607 as well 
as initial increases followed by decreases through the MCI and dementia phases, 
respectively.592,594,609 Longitudinal stability in CSF tau has also been interpreted as 
a slowing in the rate of increase due this deceleration in neuronal loss.594 Though 
a decrease in CSF tau could be due to a dilution effect,599 our application of a 
ventricular volume correction would argue against this. 
Though methodological differences, including study duration and patient selection, 
complicate comparisons, the above described data, in the aggregate, support the idea 
that negative trajectories for CSF tau may be biologically driven. Further support 
for this idea comes from a recent study that used a stable isotope labelling kinetics 
(SILK) method (involving the marking and quantification of cells marked with 
a stable isotopically labelled tracer, 13C6-leucine)610 to monitor the half-life and 
turnover rate and of tau in the human CNS.516 Applied to CU and AD subjects, 
this study suggested that while an equilibrium exists between brain  soluble tau 
and CSF tau under physiological conditions (stage A, normal), triggering events, 
including, potentially, Aβ aggregation, result in the increased production or extra-
cellular release of tau (stage B, asymptomatic). Elevated soluble tau then results in 
the seeding and spread (via mono- and trans-synaptic connections) of misfolded 
(insoluble) tau. This process is detectable using tau PET imaging, and results in a 
decrease in CSF tau (stage C, very mild AD; Braak stage I/II).611 The accumula-
tion and further spread of tau aggregates (stage D, mild AD; Braak III/IV) would 
be characterized by further decreases in CSF tau. 
Using baseline [18F]FDG, p-tau181p was inversely related to parietal SUVR; signi-
ficant negative associations were also found between tau N-Mid and [18F]FDG 
SUVR within the posterior cingulate and Braak composite regions. Tau ratios posi-
tively related to metabolism within lateral temporal (tau-368/T-tau) and isocortical 
composite (tau-368/tau N-Mid) regions. By comparison, overall findings for [18F]
FDG, in terms of the number of significant regression models, were less than half 
those for [18F]THK5317. Though considered interchangeable as biomarkers of 
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neurodegeneration,483,484 no significant associations were found between t-tau and 
[18F]FDG; previous studies addressing the relationship between t-tau and imaging 
biomarkers of neurodegeneration have shown inconsistent results in MCI and AD, 
with positive associations only mild in strength.509,514,518,520-522,612,613 Associations 
with tau N-Mid, however, were specific to [18F]FDG. These  differences between 
[18F]THK5317 and [18F]FDG suggest a temporal delay between tau pathology and 
hypometabolism,280,287 possibly due endogenous neuroprotective mechanisms,614-616 
and that tau N-Mid, in contrast to the other measures of soluble tau here investi-
gated, may capture tau related synaptic dysfunction.  
4.1.3.2 Relationship between rate of change in PET measures and CSF tau 
Considering the smaller number of subjects who underwent follow-up [18F]THK5317 
studies, the interaction term with [18F]FDG SUVR was not included, with regional 
[18F]THK5317 values instead regressed onto CSF tau measures. Based on these 
models (Figure 24), a positive association was found between p-tau181p and the 
rate of change in [18F]THK5317 DVR in the parietal cortex. As described above, 
p-tau181p was also related to parietal metabolism at baseline. This pattern of CSF 
relating to baseline [18F]FDG SUVR and to the rate of change in [18F]THK5317 
DVR within the same ROI was also seen for tau-368/t-tau (lateral temporal), 
tau-368/tau N-Mid (isocortical composite), and tau N-Mid (posterior cingulate 
and Braak regions). These findings, combined with previous  observations, provide 
further support for the idea of a nonlinear association between tau pathology and 
neurodegeneration,287,614-616 with closer correspondence during the dementia phase 
of AD.617-620 Furthermore, in light of cross-sectional associations, longitudinal 
findings associations with tau N-Mid suggest this measure may prove sensitive 
to both tangle pathology and synaptic impairment. 
4.1.3.3 Concordance between tau biomarkers
Cut-offs for [18F]THK5317 across ROIs were set using the mean DVR plus two 
standard deviations of controls (young and elderly combined). This yielded the 
following regional values: 1.11 (medial temporal lobe), 1.28 (lateral temporal lobe), 
1.29 (posterior cingulate), 1.38 (parietal lobe), 1.44 (frontal lobe), 1.34 (isocortical 
composite), 1.22 (Braak III/IV), and 1.33 (Braak V/VI). Concordance findings 
with CSF measures are summarized in Figure 25.  Across prodromal AD and AD 
dementia patients combined, agreement between [18F]THK5317 and INNOTEST 
tau measures (p-tau181p, t-tau) was approximately 50%. Overall concordance was 
similar when using N-Mid tau (53%), and improved when using tau-368 in ratio 
to t-tau (71%). Isolated [18F]THK5317 positivity was the predominant form of 
discordance when using INNOTEST measures and tau N-Mid. Using tau-368/t-tau, 
only isolated CSF positivity was found. These findings held when prodromal AD 
and AD dementia patients were analysed separately; concordance, however, was 
overall higher among AD dementia subjects.
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Concordance figures between dichotomized CSF tau and [18F]THK5317 were 
somewhat lower than those reported in the only other study to so far examine 
agreement between tau biomarkers ([18F]AV1451; p-tau181p and t-tau).514 This dis-
crepancy may relate to differences between cohorts, including age and CSF tau 
levels, the interval between CSF and tau PET, ROI selection, use of a  different 
tau tracer, and the control subjects used to define regional tau PET cut points. 
Similar to the study by Mattsson et al.,514 however, we also found that the degree 
of concordance was higher overall among AD dementia subjects in comparison 
to the prodromal AD group. This observation possibly aligns with the explana-
tion that while tau biomarkers may disagree, they will prove concordant over time 
given the chronic nature of AD.483 This reflects the fact that while CSF reflects 
production/clearance rates at a given time point, tau PET captures the cumulative 
burden of accumulated pathology. With respect to the idea of a decrease in CSF 
tau during the dementia phase of AD, higher concordance compared to prodromal 
AD might be accounted for by high baseline levels, variability across subjects, 
and increases in tau PET signal. 
Figure 24. Scatter plots showing the relationship between the annual rate of change in 
[18F]THK5317 DVR and tau-368 in ratio with T-tau and tau N-Mid (A) and between the 
annual rate of change in [18F]FDG SUVR and tau-368/T-tau (B). Multilinear regression 
model findings are summarized in the chord diagram (C), with each band indicating a 
significant finding. MTL, medial temporal; LTL, lateral temporal; FRT, frontal; PAR, 
parietal; PCC, posterior cingulate; OCC, occipital; CTX, isocortical composite; LIMB, 
Braak III/IV; ISOC, Braak V/VI. 
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Figure 25. Concordance figures showing agreement between binarised regional [18F]
THK5317 DVR and CSF tau:  INNOTEST tau (A), tau N-Mid and tau-368/T-tau (B). MTL, 
medial temporal; LTL, lateral temporal; FRT, frontal; PAR, parietal; PCC, posterior 
cingulate; OCC, occipital; CTX, isocortical composite; LIMB, Braak III/IV; ISOC, 
Braak V/VI. 
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4.1.3.4 Illustrative biomarker profiles in selected AD patients
Prodromal AD
Two prodromal AD cases showing differing tau biomarker profiles are shown in 
Figure 26A and C. High cortical [18F]THK5317 uptake (surpassing cut-offs in 
all (case 1) and eight of nine (case 2) ROIs, respectively) and temporoparietal 
hypometabolism was noted in both individuals at baseline. Using P-tau181p and 
T-tau, case 1 was concordant positive with [18F]THK5317, while CSF levels were 
below cut-offs in case 2. Longitudinally, case 1 showed increased [18F]THK5317 
retention, mainly in temporal and parietal regions, with decreased metabolism in 
the lateral temporal, posterior cingulate, and parietal cortex; case 2 also exhibited 
increased [18F]THK5317 DVR in posterior regions, though with more widespread 
changes in metabolism. CSF levels of N-Mid tau in case 1 were nearly double 
those of case 2; this difference also held for tau ratios. Tau-368 levels, however, 
were similar. At clinical follow-up, case 1 showed cognitive decline and received 
a diagnosis of AD dementia; by contrast, case 2 showed relative cognitive stability 
and retained the diagnosis of prodromal AD. 
AD dementia
Two cases of AD dementia showing concordant and discordant tau biomarker 
profiles are shown in Figure 26B and C. Using P-tau181p and T-tau, the first patient 
(case 3) showed a concordant positive profile, while the second (case 4) showed 
only [18F]THK5317 positivity. At baseline, both showed high [18F]THK5317 DVR 
values in cortical regions (above cut-offs in all regions, save for a borderline value 
in the posterior cingulate of case 4) and low [18F]FDG SUVR in temporal, parietal, 
and frontal regions. Increased retention of [18F]THK5317 was noted in frontal 
and parietal regions longitudinally for both cases, with case 3 showing additional 
involvement of temporal areas. Both patients showed metabolic decline, predomi-
nantly in temporal areas. Large differences were seen in N-Mid tau-368 and tau-
368/tau N-Mid; both patients showed similar values, however, for tau-368/T-tau. 
Cognitively (MMSE), no decline was seen in case 3 at follow-up, while a decline 
of 2 points was seen in case 4.
4.1.3.5 Interchangeability of tau biomarkers
These cases illustrate how despite the same baseline diagnosis and a similar imag-
ing profile, widely differing CSF tau profiles can be observed. Further, they high-
light how CSF tau profiles can vary in the context of low Aβ1-42, in contrast to the 
CSF signature of high tau and low Aβ1-42 expected in AD.621 In combination with 
concordance findings to date,514 these results underline the importance of recent 
recommendations for the interpretation of ambiguous CSF results in the work up 
of patients presenting with cognitive impairment,523,524 and suggest that CSF and 
tau PET biomarkers may not be invariably interchangeable.
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4.1.4 Papers IV and V – [18F]THK5317 perfusion 
 parameters in relation to [18F]FDG PET
4.1.4.1 Selection of [18F]THK5317 perfusion SUVR interval 
In order to determine the time interval for [18F]THK5317 p-SUVR, several initial 
starting points (0, 1, and 2 min) and frame durations (1 to 10 min) were used. 
Using a subset of nine patients (four prodromal AD, five AD dementia), the optimal 
interval for p-SUVR was then determined as that providing the highest correlation 
between p-SUVR and both [18F]FDG and R1 across ROIs (0-3 min). For [11C]PIB, 
a time window of 1–8 min was used based on previous findings showing that this 
interval provided the highest correlation between p-SUVR and both [18F]FDG and 
K1.336 In other studies using p-SUVR from [11C]PIB and [18F]AV45, similar time 
Figure 26. Imaging and CSF profiles for patients with baseline diagnoses of prodromal 
AD (A, C), and AD dementia (B, C). As P-tau181p and T-tau are established measures in 
the clinical work-up of dementia disorder patients, these were selected to define con-
cordance (A,B). [18F]THK5317 positivity was ascribed owing to the high percentage 
of ROIs showing DVR values above THK-control defined cut-offs. 
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intervals have been reported (0-6;343 1-4566; 1-6622; 1.33-8 min342; and 1-6 min,623,624 
respectively). In the only other study to thus far derive p-SUVR from a tau tracer 
([18F]AV1451), the interval 1-6 min was selected as optimal.345 Variability in the 
p-SUVR time window largely reflects methodological differences across studies; 
though the impact of small shifts around upper and lower boundaries are unlikely 
to exert much of an effect on correlation strengths, the risk of signal contamination 
from specific binding should be kept in mind. 
4.1.4.2 Reproducibility of [18F]THK5317 perfusion parameters
In study V, the reproducibility (test-retest variability: [(Retest – Test)/ Test]) of 
[18F]THK5317 perfusion parameters was investigated in a subset of five patients 
(four prodromal AD, one CBS) who underwent two [18F]THK5317 scans within an 
interval of 37 days. Using an isocortical meta-ROI, the average absolute  difference 
between scans across subjects was 2.43% for p-SUVR, and 3.13% for R1. Test-
retest variability in individual ROIs was also low. For example, in the parietal and 
posterior cingulate cortices, regions of high interest in AD, reproducibility esti-
mates were 4.18% and 3.10%, respectively, for p-SUVR, and 3.11% and 3.78%, 
respectively, for R1. By comparison, an average isocortical composite test-retest of 
approximately 4.5% has been reported for fluorine-18 labelled amyloid ligands,625 
with reports of between ~1.5% ([18F]AV1451)626 and 1.8% ([18F]THK5317)280 for 
tau  imaging. In addition to the evaluation of tracers’ utility in studies involving 
repeated measurements (such as those measuring treatment effects), test-retest 
studies can also provide useful information for selection of optimal quantifica-
tion methods and more broadly, for understanding measurement variability across 
regions of the brain.627 
4.1.4.3 [18F]THK5317 perfusion parameters in comparison to [18F]FDG 
In study IV, both [18F]THK5317 p-SUVR and R1 were found to positively correlate 
with [18F]FDG, with the highest coefficients observed in the lateral temporal,  parietal 
and occipital cortices. [18F]THK5317 p-SUVR and R1 were found to strongly cor-
relate positively, as did perfusion parameters from [18F]THK5317 and [11C]PIB. 
Representative images of these measures are shown in Figure 27. Voxel-wise 
analyses revealed a similar pattern (Figure 28), with widespread positive correla-
tion between [18F]THK5317 perfusion parameters and [18F]FDG; Reperformance 
of these cross-sectional analyses in study V using a subset of subjects from study 
IV yielded similar results, using both baseline and follow-up data. Overall, cross-
sectional findings from these two studies matched well with the literature showing 
that p-SUVR and R1 from amyloid ligands ([11C]PIB and [18F]AV-45)336,342,343,566,622-624 
and [18F]AV1451 tau imaging345 strongly relate to [18F]FDG metabolic imaging 
PET, using both ROI and voxel-based analyses, as well as visual comparison of 
images. Regional variability in correlational strength and percentage of shared 
variance, however, suggest that though grossly similar, CBF and metabolism may 
not relate in a one-to-one fashion throughout the brain. 
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Figure 27. Comparison of perfusion images (p-SUVR and R1) from [18F]THK5317 and 
[11C]PIB with [18F]FDG in a patient with prodromal AD (top row) and AD dementia 
(bottom row). Adapted from Rodriguez-Vieitez E, Leuzy A, Chiotis K, Saint-Aubert L, 
Wall A, Nordberg A. Comparability of [18F]THK5317 and [11C]PIB blood flow proxy 
images with [18F]FDG positron emission tomography in Alzheimer’s disease. J Cereb 
Blood Flow Metab. 2016. 
Figure 28. Biological Parametric Mapping derived voxel-wise Pearson’s correlation maps 
in 20 patients with AD (p<0.001, uncorrected; cluster extent > 20 voxels): [18F]THK5317 
p-SUVR vs [18F]FDG (left), [18F]THK5317 R1 vs [18F]FDG (middle) and [18F]THK5317 
p-SUVR vs R1 (right). Adapted from Rodriguez-Vieitez E, Leuzy A, Chiotis K, Saint-Aubert L, 
Wall A, Nordberg A. Comparability of [18F]THK5317 and [11C]PIB blood flow proxy images 
with [18F]FDG positron emission tomography in Alzheimer’s disease. J Cereb Blood Flow 
Metab. 2017; 37(2):740-749.
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In study V, voxel-wise annual percentage change for [18F]THK5317 perfusion 
measures and [18F]FDG was investigated (Figure 29). Though p-SUVR and R1 
both showed similar changes in lateral temporal and parietal areas, greater change 
was seen for p-SUVR in cingulate, prefrontal, and orbitofrontal cortices, as well as 
in the precuneus and occipital cortex. Changes in [18F]FDG were predominant in 
temporal, medial parietal, and prefrontal regions, and showed greater overlap with 
declines in p-SUVR, relative to R1. Further, comparison of binarised  percentage 
change maps for each measure showed that the overlap between metabolism and 
R1 was greatest in temporoparietal areas, with a more frontal predominant  pattern for 
p-SUVR. These observations strengthened the notion of disruptions to neurovascular 
coupling in AD, and underscored the question of interchangeability between perfu-
sion measures. Further, the limited overlap (medial temporal) observed between 
p-SUVR and areas showing increased [18F]THK5317 DVR (frontal, temporal and 
occipital) highlighted the concept of a spatiotemporal offset between pathophysio-
logical processes in AD. 
Hypothesizing that the relationship between PET measures might vary as a func-
tion of disease stage, correlation analyses were repeated by sub-group (prodromal 
AD, AD dementia) (Figure 30). These showed that while the overlap between [18F]
THK5317 perfusion parameters and [18F]FDG maps was greater in AD dementia; 
spatial correspondence between p-SUVR and R1, however, was seemingly greater 
in prodromal AD. Linear mixed modelling, including the interaction term time 
point (baseline, follow-up) x sub-group, showed that the decline in metabolism 
was comparatively greater in AD dementia. Focal increases in [18F]THK5317 DVR 
were seen in both groups; overlap with p-SUVR, however, was largely restricted 
to a small basal temporal cluster, in AD dementia. Taken together, these findings 
were interpreted as suggesting that the effects of amyloid and tau on synaptic 
integrity and cerebral vasculature differ by disease stage, with the closer align-
ment of CBF and metabolism in AD dementia possibly reflecting the loss of a glial 
phenotype that has been shown to exert a protective effect on metabolism.116,628 
While the overall inconsistencies observed between p-SUVR and R1 may relate 
to how these parameters are estimated,335,345 their greater spatial divergence in 
AD dementia may be due to contamination of the p-SUVR signal by very early 
binding to tau aggregates,345 an effect an effect that may have been masked by the 
threshold used to binarise the rate of change images. 
68
Figure 29. Group-level annual 
percentage change maps for per-
fusion (A, B), metabolism (C), and 
tau (D). Spatial overlap between 
images binarised using the  average 
test-retest repeatability of [18F]
THK5317 perfusion measures is 
shown for [18F]THK5317  perfusion 
measures (E), [18F]THK5317 
p-SUVR and [18F]FDG SUVR (F), 
and [18F]THK5317 R1 and [18F]
FDG SUVR (G). For the  overlap 
between perfusion and [18F]
THK5317 DVR (H), [18F]THK5317 
p-SUVR was chosen because of 
the potentially greater clinical 
applicability of this measure due 
the fact that it does not require 
dynamic imaging and the fact that 
identical overlap was obtained 
when using [18F]THK5317 R1. 
Adapted from Leuzy A, Rodriguez-
Vieitez E, Saint-Aubert L, et al. 
Longitudinal uncoupling of cerebral 
perfusion, glucose metabolism, 
and tau deposition in Alzheimer’s 
disease. Alzheimers Dement. 
2018;14(5):652-663. 
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Figure 30. Subgroup-level (prodromal AD, AD dementia) annual percentage change 
maps for perfusion (A, B), metabolism (C), and tau (D). Spatial overlap between 
images binarised using the average test-retest repeatability of [18F]THK5317 perfusion 
measures is shown for [18F]THK5317 perfusion measures (E), [18F]THK5317 p-SUVR 
and [18F]FDG SUVR (F), and [18F]THK5317 R1 and [18F]FDG SUVR (G). For the over-
lap between perfusion and [18F]THK5317 DVR (H), [18F]THK5317 p-SUVR was chosen 
because of the potentially greater clinical applicability of p-SUVR due the fact that it 
does not require dynamic imaging and the fact that identical overlap was obtained when 
using [18F]THK5317 R1. Adapted from Leuzy A, Rodriguez-Vieitez E, Saint-Aubert L, 
et al. Longitudinal uncoupling of cerebral perfusion, glucose metabolism, and tau depo-
sition in Alzheimer’s disease. Alzheimers Dement. 2018;14(5):652-663.
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4.1.4.4 Discriminative ability of [18F]THK5317 perfusion parameters 
In study IV, the accuracy of [18F]THK5317 perfusion parameters with respect to 
the discrimination of prodromal AD vs AD dementia patients was investigated 
using AUC area under the curve values derived from ROC analyses. These were 
compared to those for [11C]PIB perfusion parameters and [18F]FDG SUVR. No 
significant differences were found between values, however, indicating that these 
measures performed equally well in separating these two groups. These findings 
accord with previous studies that compared the diagnostic accuracy of [11C]PIB 
p-SUVR566 and [123I]IMP-SPECT339 with [18F]FDG, though other studies showed 
slightly superior performance for [11C]PIB p-SUVR336 and [18F]FDG.342 Of inter-
est, however, was the observation that perfusion to metabolism ratios,623 using 
both [18F]THK5317 and [11C]PIB differed slightly by brain region, aligning with 
previous findings showing relative hyper- and hypoperfusion, compared to  glucose 
metabolism, of limbic and cortical regions, respectively.629 Future studies will be 
required to clarify the potential impact of this, particularly with respect to the 
separation of AD from disorders that are affected by mainly subcortical pathology. 
4.2 METHODOLOGICAL CONSIDERATIONS
4.2.1 PET based measures
PET based measures used in the present thesis included SUVR (studies I-V), p-SUVR 
and SRTM R1 (studies IV-V), and reference Logan DVR (studies III and V). As these 
measures were all derived from reference tissue methods, common to them are a 
number of assumptions for reference tissues, including the suitability of a 1-TC 
model to describe ligand kinetics, negligible blood volume contribution, a lack of 
specific/displaceable binding, and the same non-displaceable volume of distribu-
tion as target regions.630 Although important, violations to these assumptions and 
the related impact of this were not directly addressed in this thesis. Though recent 
evidence suggests off-target binding of [18F]THK5351 to MAO-B,304,631,632 it remains 
unclear how well this extrapolates to findings with [18F]THK5317,306,633  particularly 
given the very low levels of MAO-B across the neocortex and cerebellar GM.634 
4.2.1.1 Partial volume correction 
In the present thesis, [18F]THK5317 PET data was pre-processed using PMOD. 
Using this software, two approaches exist for partial volume correction: the Müller-
Gärtner (MG) method219 and the geometric transfer matrix (GTM) method.635 
Though both rely on anatomical information from structural imaging and provide 
correction for both spill-in and spill-out,563 the former provides a GM specific 
correction at the voxel level, while the latter provides a regional correction after 
having segmented the brain into distinct ROIs. Due to the combination of the GTM 
not taking into account signal variability within regions (i.e. activity within each 
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region is assumed to be homogeneous) and the focality of findings with tau PET, 
the MG method was selected over the GTM for study III. Accordingly, dynamic 
[18F]THK5317 studies were first corrected voxel-wise; kinetic modelling was 
then performed on the PVE-corrected images, with ROI DVR values extracted 
via application of the Hammers atlas to parametric images.
4.2.2 CSF measurements
In study I, historical INNOTEST Aβ1-42 values were included from several cen-
tres belonging to the BIOMARKAPD project. These values had been determined 
locally as part of routine clinical practice, with CSF samples thus analysed sample 
by sample, as opposed to batch-wise. Though board-certified laboratory techni-
cians performed all analyses according to kit-inserts, using procedures accredited 
by national certification and inspection bodies, participation in the Alzheimer’s 
Association QC program varied.417,427,428 As such, the longitudinal stability of 
measurements may have differed somewhat across the included laboratories; this, 
in turn, could have impacted the cross-sectional measurements included. While 
unlikely to have exerted a large effect on our findings, this variable participation, 
combined with the use of two different commercial assays, was suboptimal from 
a methodological standpoint given the aim to directly compare concordance rates 
using local and central results.579
4.2.3 Biomarker cut-offs
Continuous biomarker measures are often dichotomized as positive or negative in 
order, for instance, to facilitate clinical decision making or to simplify statistical 
analyses in a research framework. A number of statistical approaches exist for cut-
point selection, ranging from setting sensitivity and specificity apriori to accuracy 
maximization.636 Broadly speaking, cut-point selection involves the determination 
of an acceptable balance between the risk of falsely classifying a non-diseased 
individual as diseased (false positive) and vice versa (false negative), with this 
trade-off dependent on the context in which the measure is to be applied.636 The 
approaches used in this thesis relied mainly on normal reference limits; a  possible 
limitation of this is the inadvertent inclusion of subjects who, while being negative 
for amyloid or tau at the time-point of inclusion, may show increases longitudi-
nally. Similarly, while mixture modelling assumes that the overall sample in fact 
consists of two distinct subpopulations (one with AD pathology, the other without), 
subjects instead likely lie on a continuum of AD pathology, complicating inter-
pretation of the identified mixture components.637 Ultimately, only an extended 
follow-up period (i.e. to post-mortem) would allow for an accurate assessment of 
how well these dichotomized biomarkers perform with respect to AD pathology.
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5 CONCLUDING REMARKS
• Visual based assessment of [11C]PIB scans was comparable across centres, with 
standardisation of SUVR data feasible using the Centiloid method. Centralized 
batch-wise re-analysis of CSF for Aβ1-42 did not invariably improve agreement 
with [11C]PIB imaging. This suggests a biological component to discordance, 
as opposed to this phenomenon merely reflecting methodological aspects of 
PET or CSF processing. Findings using Aβ1-42/Aβ1-40 support its use instead 
of Aβ1-42 alone.
• Amyloid imaging with [18F]flutemetamol PET exerted a meaningful impact 
in terms of diagnostic change and altered drug treatment among diagnosti-
cally uncertain tertiary memory clinic patients. These findings, paired with 
the current literature on this topic and the extensive biomarker investigations 
performed in the majority of patients prior to [18F]flutemetamol, support the 
utility of amyloid imaging in clinical practice.
• CSF tau may show both positive and negative correlations with tau PET, 
possibly as a function of neurodegeneration. In contrast to established CSF 
tau measures (i.e. p-tau181p, t-tau), novel fragments (i.e. tau N-Mid and tau-368, 
alone, or incorporated into ratios, (tau-368/tau N-Mid, tau-368/T-tau) may 
better capture both cross-sectional and longitudinal findings with tau and 
[18F]FDG PET. 
• Cross sectional findings support the use of tau PET derived perfusion measures 
(p-SUVR and R1) as alternatives for metabolic imaging with [18F]FDG PET. 
Longitudinal observations, however, suggest that the coupling between CBF 
and metabolism, as well as the interchangeability of perfusion metrics, may 
vary across both the course of AD and brain regions.
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6 FUTURE OUTLOOK
The increasing use of CSF measures and PET in clinical settings (amyloid and [18F]
FDG, with tau PET imaging likely soon to follow), and the current view of AD as 
a biological construct – definable using biomarkers for its core neuropathological 
features – highlights the relevance of understanding how they interrelate. However, 
fairly large scale longitudinal studies incorporating serial CSF and imaging in 
individuals across the AD continuum, and in related disorders, will be required to 
properly address this question. Further studies comparing CSF and PET biomark-
ers with those based in blood are also of importance given the advantages carried 
by plasma measures.638 Though further studies addressing the cost-effectiveness of 
amyloid PET are required, accrued evidence thus far indicates that it carries clinical 
utility based on its impact on changes in diagnosis, diagnostic confidence, number 
of ancillary investigations, and patient treatment. Finally, given the flexibility of 
the recently proposed A/T/N classification scheme for biomarkers used in AD and 
research on brain aging, additional studies are warranted addressing the use of perfu-
sion imaging as a substitute for neurodegeneration, via comparison to [18F]FDG and 
related markers of neuro degeneration, including CSF t-tau, neurogranin, and NFL. 
6.1 PET AND CSF BIOMARKERS FOR AMYLOID, TAU, 
AND NEURODEGENERATION
Studies addressing concordance between amyloid biomarkers show a level of 
agreement that is high, but imperfect; studies for tau biomarkers, though few in 
number, show lower rates of agreement lower than those for amyloid. Explanations 
for disagreement include variability in Aβ production levels, isolated low CSF 
Aβ1-42 in non-AD disorders, and, for tau, possibly, that CSF levels vary over the 
disease course. Cut-offs used to define abnormality in CSF are also relevant; due 
the lack of common calibrators, a multitude of values are currently used for defin-
ing abnormal measurements. Standardisation efforts have so far come the furthest 
for Aβ1-42, with the publication of two MS-based RMPs, now certified by the Joint 
Committee for Traceability in Laboratory Medicine,429,639 and a CSF-based refer-
ence material currently under evaluation.640 These developments, combined with 
fully automated assays carrying low coefficients of variation,526 should move the 
field closer to the introduction of universal cut-offs for defining abnormal Aβ1-42 
values. Similar advances will hopefully soon follow for tau, with one candidate 
RMP for t-tau recently reported.641 In the interim, recent work using one such 
automated assay has shown 90% concordance between CSF (tau/Aβ1-42 ratios) 
and amyloid PET;642 the fact that this resulted from tau in ratio with Aβ1-42 also 
highlights comparative studies between these measures and Aβ1-42 in ratio with 
shorter Aβ peptides as an important line of research. Lastly, further exploration of 
novel tau fragments that better track the development of neurofibrillary pathology 
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will likely be required to achieve optimum concordance with tau PET imaging, 
as are studies addressing the proposed reclassification of t-tau as a marker of 
neurodegeneration.483
While visual reads remain the standard for amyloid PET in clinical practice, with 
this approach likely to also be used with tau imaging should it become approved 
for clinical use, quantitative approaches carry advantages, including reduced inter-
reader variability, and higher sensitivity.643-645 Using the Centiloid method, amyloid 
PET findings can be brought into the same range of values, potentially facilitating 
large scale comparative studies with CSF. Recent findings, however, suggest that 
this approach does not entirely eliminate differences between analytical approaches, 
resulting in, for instance, different sensitivity to changes in amyloid burden and 
varied amyloid positivity thresholds.646 Incorporation of neuropathology findings 
may help solve these issues.584,647 Similar approaches to standardise quantitative 
tau imaging measures will be required; this may prove more challenging, however, 
given the different spatiotemporal pattern of progression tau is thought to follow.
The above described approaches should, ultimately, facilitate large scale studies 
examining how PET and CSF measures relate over time, including concordance 
rates using dichotomised measures; this is critical if these biomarkers are to be 
treated as interchangeable. The current literature suggests discordance between 
amyloid biomarkers is more often in the form of isolated low CSF Aβ1-42,505 with 
this type of discordance preferentially found in early disease stages (i.e. CU indi-
viduals and early MCI) and seldom in AD dementia.244 This may not hold true 
in atypical populations, however (e.g. tertiary memory clinic populations). It is 
important to stress, however, that these methods do not measure exactly the same 
thing; from a longitudinal perspective, CSF and PET biomarkers have different 
trajectories: whereas CSF Aβ1-42 and tau plateau (or possibly decrease, in the case 
of tau), early on, PET based measures remain dynamic into the later stages of the 
disease.141,514,553,648 Discordance between CSF and PET amyloid biomarkers in 
preclinical AD, for instance, may lend itself to the design of prevention trials;649 
those with isolated low Aβ1-42, for instance, may prove suitable for long-term studies 
targeting Aβ production, but not for short term trials examining the effects on an 
intervention on cognition, tau levels, or brain atrophy.
6.2 CLINICAL VALUE OF AMYLOID IMAGING AND 
GENERAL APPLICABILITY OF PERFUSION PET
In terms of our findings using [18F]flutemetamol PET, the increases in  diagnostic 
change and in the use of AChEIs, together with previous studies, confirm the 
 clinical value of amyloid PET. Further studies addressing the value of  quantitation 
in amyloid PET, using SUVR and alternative approaches,561,650 either as an adjunct 
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to, or substitute for, visual read, are required. The pairing of CBF (early phase 
SUVR or R1) and late phase information from amyloid or tau PET  imaging carries 
the advantage of being able to derive both functional and molecular information 
from a single PET study.  From a practical standpoint, however, only p-SUVR would 
be feasible in clinical settings. Dual-use PET would do away with the need for a 
separate [18F]FDG PET study, reducing costs, patient discomfort, and  radiation 
exposure. In the event that tau PET gains approval for clinical use, dual-use imaging 
would circumvent delays between [18F]FDG and tau imaging (similar to those seen 
for amyloid PET), carrying potential benefits in the form of more rapid diagnosis, 
improved patient management and decreased ordering of ancillary investigations. 
Future studies will be required to address this. The possibility of varied parallelism 
between perfusion and metabolism over the course of AD should also be inves-
tigated in longitudinal studies, with these investigations extended to also address 
the potential of this technique in related non-AD dementia disorders as well as 
the potential modulatory effects of amyloid and tau pathology, vascular load, and, 
potentially, neuroinflammation. 
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